

CURRICULUM VITAE

---

Miriam Cnop, MD, PhD

*ADDRESS*

Home: Boudewijnlaan 21  
1700 Dilbeek, Belgium  
Phone 32.2.270.37.79

Work: Division of Endocrinology, Department of Medicine, Erasmus Hospital  
and ULB Center for Diabetes Research, Faculty of Medicine  
Université Libre de Bruxelles  
808, Route de Lennik  
1070 Brussels, Belgium  
Phone 32.2.555.63.05  
Fax 32.2.555.62.39  
mcnop@ulb.ac.be

*DATE AND PLACE OF BIRTH*

December 25, 1970, Elsene, Belgium

*NATIONALITY*

Belgian

*LANGUAGES*

Dutch (mother tongue), English (fluent), French (fluent), German (basic), Portuguese (basic)

*EDUCATION*

HIGH SCHOOL

1982-1988      Orientation Latin/Mathematics, Royal Atheneum Tervuren, Belgium

UNIVERSITY

Graduate Vrije Universiteit Brussel, Brussels, Belgium

1988-1995      Medical Doctor

*Summa cum Laude*

*Magna cum Laude*

*Magna cum Laude*

*Magna cum Laude*

*Summa cum Laude*

*Summa cum Laude*

*Summa cum Laude*

First Prize of the Faculty Jury for the Best Medical Curriculum  
Graduate thesis: 'Effects of lipids on rat pancreatic  $\beta$  cells', Diabetes Research  
Center, Vrije Universiteit Brussel (Supervisor Prof D Pipeleers)

Post-graduate

## *Curriculum vitae Miriam Cnop*

- 1995-2002 PhD program, Faculty of Medicine, Vrije Universiteit Brussel, Brussels, Belgium (Supervisor Prof Daniel Pipeleers)  
Supported by a scholarship of the Belgian Fund for Scientific Research (Aspirant FWO)  
Title of the PhD thesis 'Lipids, putative  $\beta$  cell pathogens in type 2 diabetes' (date of defense: May 2002)
- 1995-2001 Specialization in Internal Medicine, Vrije Universiteit Brussel, Belgium
- 2000-2001 Post-doctoral Fellow, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, USA (Supervisor Prof Steven E Kahn)
- 2001-2002 Specialization in Endocrinology, Department of Medicine, Vrije Universiteit Brussel, Brussels, Belgium
- 2002-2003 Specialization in Endocrinology, Department of Medicine, Université Libre de Bruxelles, Brussels, Belgium

### *LICENSURE AND CERTIFICATION*

- 1995 Medical Practice License, Brussels, Belgium  
2001 Internal Medicine Certification, Brussels, Belgium  
2010 Endocrinology Certification, Brussels, Belgium

### *APPOINTMENTS*

- 1995-1999 Scholarship of the Belgian Fund for Scientific Research (Aspirant FWO)  
Diabetes Research Center, Vrije Universiteit Brussel, Belgium  
Combined clinical (residency) and scientific (PhD) training
- 1999-2000 Medical Resident, Department of Medicine, Academisch Ziekenhuis Vrije Universiteit Brussel, Belgium
- 2000-2001 Senior Research Fellow in the Division of Metabolism, Department of Medicine, University of Washington, Seattle, Washington, USA  
Supported by a scholarship of the Belgian American Educational Foundation
- 2001-2002 Endocrinology Fellow, Department of Medicine, Academisch Ziekenhuis Vrije Universiteit Brussel, Belgium
- 2002-2003 Endocrinology Fellow, Department of Medicine, Erasmus Hospital  
Research Fellow, Laboratory of Experimental Medicine, Université Libre de Bruxelles, Brussels, Belgium
- 2003-2007 Staff Physician (Résident), Division of Endocrinology, Department of Medicine, Erasmus Hospital, Brussels, Belgium  
Research Fellow, Laboratory of Experimental Medicine, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- 2005-2010 Halftime Research Fellowship of the Belgian Fund for Medical Scientific Research (FRSM) at the Laboratory of Experimental Medicine, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- 2007-2016 Deputy Head of Clinic (Chef de Clinique Adjoint), Division of Endocrinology, Department of Medicine, Erasmus Hospital, Brussels, Belgium
- 2010-present Visiting professor at Hunan Agricultural University, Changsha, China
- 2011-present Halftime tenured Associate Professor (Chargé de Cours), Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- 2016-present Professor, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 2016-present Clinical Director (Directeur de Clinique), Division of Endocrinology, Erasmus Hospital, Brussels, Belgium

**MEMBERSHIP IN PROFESSIONAL SOCIETIES**

American Diabetes Association (ADA)  
American Society for Biochemistry and Molecular Biology  
Belgian Association for the Study of Obesity  
Belgian Diabetes Association  
Belgian Endocrine Society  
The Endocrine Society (USA)  
European Association for the Study of Diabetes (EASD)  
European Association for the Study of Obesity  
International Association for the Study of Obesity  
Fellow of the Belgian American Educational Foundation

**SCIENTIFIC AWARDS AND SCHOLARSHIPS**

Graduation: First Prize of the Faculty Jury for the Best Medical Curriculum, 1995  
Aspirant of the Belgian Fund for Scientific Research (FWO), 1995-1999  
Selected among the 5 best abstracts for the Orbita Congress Speakers' prize Belgium, 2000, with the lecture: 'Dyslipidemia: a new risk factor for the development of diabetes mellitus type 2?'  
Fellow of the Belgian American Educational Foundation, Belgium, 2000  
Fellow of the D. Collen Research Foundation, Belgium, 2000  
Fellow of the Hoover Foundation Brussels, Belgium, 2000  
Fellow of the Medische Stichting Horlait-Dapsens, Belgium, 2000  
Victor Lange Prize for Diabetes Research in Belgium, 2003  
Prize from the Jean De Meyer Foundation for Research in Endocrinology, awarded by the Royal Academy of Science of Belgium, 2003  
Novo Nordisk Prize for Diabetology, Belgium, 2004  
Honorary Fellow of the Erasmus Foundation Brussels, Belgium, 2004  
Fellow of the Belgian Fund for Medical Scientific Research (FRSM), 2005-2010  
Young Investigator Award of the Belgian Endocrine Society, Brussels, Belgium, 2004  
"Rising Star" of the European Association for the Study of Diabetes, 2005  
Prize - Research Award from the Octave Dupont Foundation, awarded by the Royal Academy of Science of Belgium, 2005  
Young Investigator Award of the National Ataxia Foundation, USA, 2007  
Sanofi-Aventis Award in Diabetes, Belgium, 2007  
GB Morgagni Young Investigator Award, awarded under the auspices of the School of Medicine of the University of Padua, Italy, 2010  
Belgian Endocrine Society Annual Lecture Award, Belgium, 2010  
Oskar Minkowski Prize of the European Association for the Study of Diabetes, 2013  
Auguste Loubatières Prize of the French Diabetes Society, 2014

**RESEARCH GRANTS**

European Foundation for the Study of Diabetes - Johnson & Johnson Type 2 Diabetes Research Grant (Co-applicant). Title: Molecular mechanisms of  $\beta$  cell apoptosis induced by adipocyte-derived mediators in type 2 diabetes mellitus. Period: 2003-2005. Total amount of support: € 100,000.

David & Alice Van Buuren Foundation Research Grant (Principal Investigator). Title: Molecular mechanisms of  $\beta$  cell apoptosis in type 2 diabetes: role of free fatty acids and adipokines. Period: 2005. Total amount of support: € 13,000.

European Foundation for the Study of Diabetes – Novo Nordisk Programme for Diabetes Research (Principal Investigator). Title: Endoplasmic reticulum stress: a putative cause of nutrient- and obesity-induced pancreatic  $\beta$ -cell dysfunction and death in type 2 diabetes. Period: 2005-2006. Total amount of support: € 100,000.

Belgian Lipid Club Research Fellowship 2005 (Principal Investigator). Title: Free fatty acids are the effectors of nutrient- and obesity-induced  $\beta$ -cell loss in type 2 diabetes via induction of endoplasmic reticulum stress. Period: 2006. Total amount of support: € 12,500.

Research Award from the Octave Dupont Foundation, awarded by the Royal Academy of Science of Belgium (Principal Investigator). Title: Endoplasmic reticulum stress: a putative cause of nutrient- and obesity-induced pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes. Period: 2006-2007. Total amount of support: € 12,500.

European Union FP6 Integrated Project (Co-applicant). Acronym: EURODIA. Title: Functional genomics of pancreatic  $\beta$  cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes. Period: 2006-2010. Total amount of support: € 416,000.

Young Investigator Award of the National Ataxia Foundation USA (Principal Investigator). Title: Pathogenesis of impaired glucose tolerance and diabetes in Friedreich's ataxia: contribution of insulin resistance and pancreatic beta cell dysfunction. Period: 2008-2009. Total amount of support: \$ 100,000.

European Foundation for the Study of Diabetes – Lilly European Diabetes Research Programme (Principal Investigator). Title: Mitochondrial dysfunction in insulin resistance and pancreatic  $\beta$  cell failure - role in the pathogenesis of diabetes in Friedreich's ataxia. Period: 2009. Total amount of support: € 100,000.

European Union FP7 Collaborative Project (Principal Investigator). Acronym: CEED3. Title: Collaborative European Effort to Develop Diabetes Diagnostics. Period: 2008-2012. Total amount of support: € 196,000.

French Association for the Study of Diabetes - Alfediam (Principal Investigator). Title: The pathogenesis of diabetes in Friedreich's ataxia - combining patient studies and experimental transgenic models to identify novel therapies for frataxin deficiency. Period: 2009. Total amount of support: € 20,000.

European Foundation for the Study of Diabetes – Lilly European Diabetes Research Programme (Principal Investigator). Title: Stress relief or anti-apoptotic defense? Mechanisms of GLP-1 protection against lipotoxic endoplasmic reticulum stress in pancreatic  $\beta$  cells. Period: 2010. Total amount of support: € 100,000.

Concerted Research Action (Actions de Recherche Concertée), Belgium (Principal Investigator). Title: Discovery of the molecular pathways regulating pancreatic  $\beta$  cell dysfunction and apoptosis in diabetes using functional genomics and bioinformatics. Period: 2010-2015. Total amount of support: € 217,980.

European Union FP7 Collaborative Project (Principal Investigator). Acronym: BetaBat. Title: Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes. Period: 2011-2015. Total amount of support: € 504,000.

European Foundation for the Study of Diabetes – Novo Nordisk Partnership for Diabetes Research in Europe (Principal Investigator). Title: The DNA methylation landscape of type 2 diabetes. Period: 2011-2012. Total amount of support: € 220,000.

Belgian Fund for Scientific Research (FNRS) - Fund for Medical Scientific Research (FRSM) (Principal Investigator). Title: DNA methylation in type 2 diabetes. Period: 2012-2015. Total amount of support: € 377,500.

Erasmus Fund for Medical Research – Olivia De Clercq research grant, Belgium (Principal Investigator). Title: Understanding cellular dysfunction and apoptosis in Friedreich ataxia – towards novel cell therapies for frataxin deficiency. Period: 2012-2013. Total amount of support: € 160,000.

Belgian Fund for Scientific Research (FNRS) – Fund for Medical Scientific Research (FRSM) (Principal Investigator). Title: Identification of novel pathways of  $\beta$  cell dysfunction and death in type 2 diabetes by transcriptomic profiling of human islets. Period: 2013. Total amount of support: € 30,000.

Friedreich's Ataxia Research Alliance USA – Phillip Bennett and Kyle Bryant Translational Research Award (Principal Investigator). Title: Incretin analogs as new therapeutics for Friedreich's ataxia. Period: 2013-2014. Total amount of support: \$ 125,000.

Belgian Fund for Scientific Research (FNRS) – Fund for Medical Scientific Research (FRSM) Incentive Grant for Scientific Research (MIS) (Principal Investigator). Title: The role of the endoplasmic reticulum and mitochondrial unfolded protein responses in pancreatic  $\beta$  cell failure in diabetes. Period: 2014-2016. Total amount of support: € 450,000.

Wallonia Public Service Programme of Excellence, Belgium (Principal Investigator). Acronym: Food4Gut. Novel nutritional approach to obesity based on colic nutrients: biological, behavioral and societal aspects. Period: 2014-2019. Total amount of support: € 764,267.

Brussels Region Innoviris, Belgium (Principal Investigator). Support for the preparation of Horizon 2020 grant applications. Period: 2014. Total amount of support: € 24,766.

Concerted Research Action (Actions de Recherche Concertée), Belgium (Principal Investigator). Title: Unveiling novel mechanisms of  $\beta$  cell dysfunction and death in diabetes. Period: 2015-2017. Total amount of support: € 220,000.

Friedreich's Ataxia Research Alliance USA – Phillip Bennett and Kyle Bryant Translational Research Award (Principal Investigator). Title: Incretin analogs as new therapeutics for Friedreich's ataxia. Period: 2015. Total amount of support: \$ 18,100.

European Union IMI Innovative Medicines Initiative (Principal Investigator). Acronym: INNODIA. Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes. Period: 2015-2022. Total amount of support: € 204,000.

Emile Defay Foundation, Université Libre de Bruxelles (Principal Investigator). Title: Development of pancreatic  $\beta$  cells from human induced pluripotent stem cells. Period: 2015. Total amount of support: € 10,935.

European Union Horizon 2020 (Coordinator). Acronym: T2DSystems. Title: Development of a systems biomedicine approach for risk identification, prevention and treatment of type 2 diabetes. Period: 2016-2019. Total amount of support: € 705,521 (total budget for the consortium € 5,998,602).

European Union IMI Innovative Medicines Initiative (Principal Investigator). Acronym: Rhapsody. Title: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification. Period: 2016-2020. Total amount of support: € 399,375.

David & Alice Van Buuren Foundation Research Grant (Principal Investigator). Title: Development of pancreatic  $\beta$  cells from human induced pluripotent stem cells. Period: 2016. Total amount of support: € 5,000.

Rotary Belgium (Co-applicant). Title: Incretin analogs as novel therapeutics for Friedreich ataxia. Period: 2016. Total amount of support: € 5,000.

Eye Hope Foundation, King Baudouin Foundation (Co-applicant). Title: GLP-1R analogs for the treatment of Wolfram syndrome. Period: 2017-2018. Total amount of support: € 93,576.

ULB Foundation (Principal Investigator). Title: Human induced pluripotent stem cell-derived pancreatic  $\beta$  cells. Period: 2017. Total amount of support: € 53,000.

Brussels region Innoviris Bridge Strategic Platforms (Coordinator). Acronym: DiaType. Title: Personalized medicine in diabetes: towards an etiology-based diagnosis and better patient care. Period: 2018-2020. Total amount of support: € 802,470 (total budget for the consortium € 2,353,285).

Belgian Fund for Scientific Research (FNRS) – Fund for Medical Scientific Research (FRSM) Research Project (Principal Investigator). Title: Genome-edited induced pluripotent stem cell-derived pancreatic  $\beta$  cells: a powerful tool for the discovery of pathogenic mechanisms and novel therapies for diabetes. Period: 2018-2021. Total amount of support: € 319,959.

## *PATENTS*

Methylation patterns of type 2 diabetes patients (Fuks, Volkmar, Eizirik, Cnop) Patent No 11151585.4 – 2402 submitted to the European Patent Office January 20, 2011, Publication No WO 2012/097203

Treatment of Friedreich's ataxia (Igoillo-Esteve, Pandolfo, Cnop) Patent application No GB20130010101.9 submitted to the European Patent Office June 6, 2013, Publication No GB 2514827

**TRAINING OF STUDENTS**

- Co-supervisor of Mrs Delma Nieves, Undergraduate Medical School research project, University of Washington, Seattle, Washington, USA (2000-2001)
- Co-supervisor of Mrs Christine Chen Jensen, Undergraduate Medical School research project, University of Washington, Seattle, Washington, USA (2000-2001)
- Supervisor of Mrs Ilham Kharroubi, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2002-2005)
- Supervisor of Mrs Carine Boven, Master's thesis, Medical School, Université Libre de Bruxelles, Brussels, Belgium (2004-2005)
- Supervisor of Mrs Deborah Silberbergh, Undergraduate Medical School research project, Université Libre de Bruxelles, Brussels, Belgium (2005)
- Supervisor of Mrs Angie Bazarra Castro, Master student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2006-2007)
- Co-supervisor of Mr Michael Maris, PhD student in Biomedical Sciences, Katholieke Universiteit Leuven, Louvain, Belgium (2006-2010)
- Supervisor of Mrs Yasmina Serroukh, Master's thesis, Medical School, Université Libre de Bruxelles, Brussels, Belgium (2008-2009)
- Co-supervisor of Mr Rodrigo Moura, PhD student in Biomedical Sciences, Universidade Estadual Paulista Júlio de Mesquita Filho, Sao Paulo, Brazil (2009-2010)
- Supervisor of Mrs Navrita Mathiah, Undergraduate Biomedical Sciences research project, Université Libre de Bruxelles, Brussels, Belgium (2011)
- Supervisor of Mrs Livia Teixeira Oliveira, Master's thesis in Pharmaceutical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2011)
- Supervisor of Mr Kevin Verstrepen, Undergraduate Biomedical Sciences research project, Université Libre de Bruxelles, Brussels, Belgium (2011)
- Supervisor of Mr Baroj Abdulkarim, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2012-2017)
- Co-supervisor of Mrs Marie-Ingrid Valliamee, Master's thesis in Public Health Sciences, Université Catholique de Louvain, Brussels, Belgium (2013-2014)
- Supervisor of Mrs Ana F Oliveira, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2013-2018)
- Co-supervisor of Mrs Cristina Cosentino, PhD student in Molecular Medicine, University of Milan, Milan, Italy (2014-2015)
- Supervisor of Mrs Teodora Oltean, Master's thesis in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2014-2015)
- Co-supervisor of Mrs Sabrina Villar Pazos, PhD student in Biomedical Sciences, Universidad Miguel Hernández, Elche, Spain (2014)
- Co-supervisor of Mrs Anne Momo Jiteu, Undergraduate Biomedical Sciences research project, Université Libre de Bruxelles, Brussels, Belgium (2014)
- Co-supervisor of Mrs Monia Cito, PhD student in Endocrinology, University of Parma, Parma, Italy (2015-2016)
- Supervisor of Mrs Maria Lytrivi, MD, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2015-present)
- Co-supervisor of Mrs Maria Ines De Oliveira Alvelos, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2015-present)
- Supervisor of Mrs Philomene Scohy, Master's thesis in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2015-2016)
- Supervisor of Mr Esteban Diaz Villamil, Master's thesis in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2016-2017)
- Co-supervisor of Mrs Marine Delvaux, Undergraduate Biomedical Sciences research project, Université Libre de Bruxelles, Brussels, Belgium (2016)

Co-supervisor of Mrs Jeanne Chabosy, Master's thesis in Dietetics, Paul Lambin Institute, Leonardo da Vinci College, Brussels, Belgium (2017)

Supervisor of Mrs Daphnee Porthault, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2016-present)

Supervisor of Mrs Jesabelle Kibanda, PhD student in Biomedical Sciences, Université Libre de Bruxelles, Brussels, Belgium (2017-present)

Co-supervisor of Mrs Federica Fantuzzi, PhD student in Endocrinology, University of Parma, Parma, Italy (2018-present)

Supervisor of Mrs Sophie Welsch, Undergraduate Biomedical Sciences research project, Université Catholique de Louvain, Brussels, Belgium (2018)

#### *SUPERVISION OF POST-DOCTORAL FELLOWS*

Dr Paul Hekerman, PhD from RWHT Aachen University, Aachen, Germany (2005-2006)

Dr Marion C Wakeham, PhD from University of Bristol, Bristol, UK (2006-2007)

Dr Daniel A Cunha, PhD from UNICAMP, Campinas, Brazil (2007-2016)

Dr Mariana Igoillo-Esteve, PhD from UNSAM, Buenos Aires, Argentina (2007-2016)

Dr Miriam Hernangómez, PhD from Cajal Institute, Madrid, Spain (2011-2012)

Dr Kassem Ghaddar, PhD from Université Libre de Bruxelles, Brussels, Belgium (2014-2016)

Dr Daniela Nasteska, PhD from Kyoto University, Kyoto, Japan (2014-2015)

Dr Miguel Lopes, PhD from Université Libre de Bruxelles, Brussels, Belgium (2014-present)

Dr Pratibha Singh, PhD from Jawaharlal Nehru University, Lucknow, India (2015-2016)

Dr Cristina Cosentino, PhD from University of Milan, Milan, Italy (2016-present)

Dr Monia Cito, PhD from University of Parma, Parma, Italy (2016-2017)

Dr Sanna C Toivonen, PhD from University of Helsinki, Helsinki, Finland (2016-present)

Dr Paraskevi Salpea, PhD from University of Athens, Athens, Greece (2017-present)

#### *TEACHING*

Member of the post-graduate course in endocrinology of the Université Libre de Bruxelles, Belgium (2006-present)

'Molecular endocrinology', Master program in biochemistry and molecular and cell biology, specialization in molecular pathophysiology, jointly organized by the Faculties of Science of the Université Libre de Bruxelles and the University of Mons, Belgium (2010-2014)

'Pathophysiology of type 1 diabetes', Medical School, University of Geneva, Switzerland (2012)

'Scientific Communication', Medical School and Institute of Biology, UNICAMP, Campinas, Sao Paulo, Brazil (2013)

'Endocrinology and metabolism – diabetology and metabolic diseases', Master program in medicine, Faculty of Medicine, Université Libre de Bruxelles, Belgium (2014-present)

'Repurposing of GLP-1 analogs: from diabetes to neurodegenerative diseases', ULB Certificate in Translational Medicine, Faculty of Medicine, Université Libre de Bruxelles, Belgium (2016)

'Academic clinical research', ULB Certificate in Translational Medicine, Faculty of Medicine, Université Libre de Bruxelles, Belgium (2018)

Member of the College of Translational Medicine of the Université Libre de Bruxelles, Belgium (2017-present)

#### *COMMITTEE FOR THE ACCOMPANIMENT OF PhD STUDENTS (ULB, Brussels, Belgium)*

Mr Idrissi Ahmed, PhD student of the School of Public Health (2012-present)

Mrs Lin Jiang, PhD student in Biomedical Sciences, Laboratory of Pharmacodynamics and Therapeutics (2012-2013)

Mrs Jeanne Chiadak, PhD student in Biomedical Sciences, Laboratory of Pathophysiological and Nutritional Biochemistry (2012-2015)

Mr Fadi Charara, PhD student in Medical Sciences (2017-present)

*INTERNAL EVALUATION OF PhD THESES (ULB, Brussels, Belgium)*

Mrs Candice Hoste, PhD student in Biomedical Sciences, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (November 17, 2011)

Mrs Eleonore Dubois, PhD student in Biomedical Sciences, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (August 27, 2012)

Mr Cedric Jurysta, PhD student in Biomedical Sciences, Laboratory of Experimental Hormonology (January 13, 2015)

Mrs Beatriz Alvaro Mercadal, PhD student in Medical Sciences, Department of Gynecology, Erasmus Hospital (September 1, 2015)

Mr Luigi Moretti, PhD student in Medical Sciences, Department of Radiotherapy, Jules Bordet Institute (October 7, 2015)

Mrs Patrizia Loi, PhD student in Medical Sciences, Department of Gastroenterology, Erasmus Hospital (February 15, 2016)

*EXTERNAL EXAMINER OF PhD THESES*

Mrs Aurelie Delaigle, PhD student in Biomedical Sciences, Unité d'Endocrinologie et Metabolisme, Université Catholique de Louvain, Brussels, Belgium (September 28, 2006)

Mrs Malin Fex, PhD student in Biomedical Sciences, Division of Diabetes, Metabolism, and Endocrinology, Lund University, Lund, Sweden (November 10, 2006)

Mrs Hanna Nyblom, PhD student in Biomedical Sciences, Department of Medical Cell Biology, University of Uppsala, Uppsala, Sweden (December 8, 2007)

Mrs Katherine Pinnick, PhD student in Biomedical Sciences, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK (February 15, 2008)

Mrs Romana Stark, PhD student in Biomedical Sciences, Medical University of Vienna, Vienna, Austria (March 25, 2012)

Mrs Liselotte Fransson, PhD student in Biomedical Sciences, Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden (March 21, 2014)

Mrs Nathalie Esser, PhD student in Biomedical Sciences, Division of Diabetes, Nutrition and Metabolic Disorders, University of Liège, Liège, Belgium (June 26, 2014)

Mr Romeo Cassel, PhD student in Biomedical Sciences, Cardiovascular, Metabolism, Diabetology & Nutrition, University of Lyon 1, Lyon, France (November 21, 2014)

Mr Pieter Stijnen, PhD student in Biomedical Sciences, Laboratory of Biochemical Neuroendocrinology, Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium (December 10, 2015)

Mrs Estefania Tarifeno, PhD student in Biomedical Sciences, Laboratory of Zebrafish Development and Disease Models, GIGA Research, University of Liège, Liège, Belgium (December 16, 2015)

Mr Nabil Rabhi, PhD student in Biomedical Sciences, Molecular Basis and Modelization of diabetes, European Genomic Institute for Diabetes, Lille 2 University, France (February 19, 2016)

Mrs Noemie Druelle, PhD student in Biomedical Sciences, Diabetes Genetics Team, University of Nice Sophia-Antipolis, Nice, France (December 2, 2016)

Mrs Jeanne Durendale Chiadak, PhD student in Biochemistry, Biochemistry Department, University of Dschang, Dschang, Cameroun (March 17, 2017)

Mrs Sze Hwee Ong, PhD student in Medicine, Dentistry and Health Sciences, University of Melbourne, Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, Victoria, Australia (September 8, 2017)



Mr Siebe Spijker, PhD student in Biomedical Sciences, Leiden University Medical Center, Leiden, the Netherlands (November 7, 2017)

Mr Marc Diederich, PhD student in Biomedical Sciences, Cochin Institute, Paris, France (November 24, 2017)

Mrs Lisa Stoll, PhD student in Biomedical Sciences, Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland (April 11, 2018)

Mrs Magalie Ravier, Habilitation à Diriger des Recherches, Institute for Functional Genomics, University of Montpellier, Montpellier, France (July 4, 2018)

## *INVITED LECTURES*

### International lectures

1. 'β cell death in experimental models of type 2 diabetes', April 30, 2004, Medical Faculty, Norwegian University of Science and Technology, Trondheim, Norway
2. 'Lipotoxicity in pancreatic β cells', European Association for the Study of Diabetes - Islet Study Group annual meeting, September 9-12, 2004, Prien/Chiemsee, Germany
3. 'The role of body fat depots and adipokines in insulin resistance, dyslipidemia and glucose intolerance', 1<sup>st</sup> Russell Berrie International Diabetes Symposium, October 17-19, 2004, Jerusalem, Israel
4. 'From bedside to bench: the role of fat in β-cell loss in type 2 diabetes', Rising Star Symposium of the 41<sup>st</sup> Annual Meeting of the European Association for the Study of Diabetes, September 10-15, 2005, Athens, Greece
5. 'Role of endoplasmic reticulum stress in β-cell loss in type 2 diabetes', Diabetes UK annual meeting, March 29-31, 2006, Birmingham, United Kingdom
6. 'Lipotoxicity and endoplasmic reticulum stress in pancreatic β-cells', June 20, 2006, Boston University School of Medicine, Boston, MA, USA
7. 'The role for endoplasmic reticulum stress in β-cell death', Integrated Project EURODIA Open Symposium on β-cell dysfunction and death in diabetes mellitus, October 24, 2006, Pisa, Italy
8. 'Lipotoxicity in β-cells: role of endoplasmic reticulum stress', November 9, 2006, Diabetes Research Center, Lund University, Malmö, Sweden
9. 'β-cell loss in type 2 diabetes - role of lipotoxicity and endoplasmic reticulum stress', May 23, 2007, Division of Endocrinology and Metabolic Disorders, Wilhelmina Kinderziekenhuis, Utrecht University Medical Center, Utrecht, the Netherlands
10. 'Fatty acids and glucolipotoxicity', Biochemical Society Focused Meeting 'The Pancreatic Beta Cell: Birth, Life & Death', December 4-5, 2007, St Thomas Hospital, London, UK
11. 'The role of endoplasmic reticulum stress in lipotoxicity', Biochemical Society Focused Meeting 'Molecular mechanisms of gluco/lipotoxicity in diabetes', March 24-26, 2008, Dublin, Ireland
12. 'Mechanisms of β cell damage in type 2 diabetes', European Association for the Study of Diabetes - Islet Study Group annual meeting, September 11-13, 2008, Rome, Italy
13. 'The role of endoplasmic reticulum stress in pancreatic β cell dysfunction and death in type 2 diabetes', December 18, 2008, University of Sao Paulo, Sao Paulo, Brazil
14. 'Endoplasmic reticulum stress in diabetes', European Association for the Study of Diabetes - Study Group on Genetics of Diabetes and 44<sup>th</sup> annual meeting of the Scandinavian Society for the Study of Diabetes, April 22-25, 2009, Bergen, Norway
15. 'Endoplasmic reticulum stress mechanisms in lipotoxic β-cell dysfunction', 11<sup>th</sup> Servier-International Group on Insulin Secretion (IGIS) Symposium on "The Stressed Beta-Cell", March 25-28, 2010, St Jean Cap Ferrat, France
16. 'Initiation and execution of lipotoxic endoplasmic reticulum stress in pancreatic β-cells', Experimental Biology 2010, April 24-28, 2010, Anaheim, CA, USA
17. 'The fate of the pancreatic β cell in diabetes: lipotoxic ER stress in type 2 diabetes', May 18, 2010, Hagedorn Research Institute, Gentofte, Denmark
18. 'Lipotoxic ER stress in pancreatic β cells: mechanisms and therapy', June 16, 2010, Shanghai Jiao Tong University, Shanghai, China

19. 'Lipotoxic ER stress in pancreatic  $\beta$  cells: mechanisms and therapy', June 17, 2010, Central South University Xiangya Medical College and Hunan Agricultural University, Changsha, China
20. 'Endoplasmic reticulum stress and  $\beta$  cell demise in type 2 diabetes', Morgagni Prize lecture at the 10<sup>th</sup> European Symposium on Metabolism, October 7-9, 2010, Padua, Italy
21. 'Lipotoxic endoplasmic reticulum stress in pancreatic  $\beta$ -cells', November 25, 2010, Clinic for Internal Medicine, University of Tübingen, Germany
22. 'Pancreatic  $\beta$  cell dysfunction and insulin resistance contribute to diabetes in Friedreich's ataxia', 4<sup>th</sup> International Friedreich's Ataxia Scientific Conference, May 5-7, 2011, Strasbourg, France
23. 'Molecular mechanisms of lipotoxic  $\beta$  cell demise', European Association for the Study of Diabetes - Islet Study Group annual meeting, May 8-11, 2011, Natal, Brazil
24. 'Glucolipototoxicity and GLP-1 in the modulation of  $\beta$  cell function and survival', Robinson Crusoe meeting, June 9-10, 2011, Rome, Italy
25. 'Mechanisms of gluco/lipototoxicity and (mild) inflammation in human islets', 16<sup>th</sup> European Association for the Study of Diabetes - Hagedorn Oxford Workshop, August 5-8, 2011, Keble College, Oxford, UK
26. 'What can research offer us? Hopes and expectations of people with diabetes', EURADIA Symposium 'Shaping the future of research in Europe for the benefit of people with diabetes' September 12, 2011, Lisbon, Portugal
27. 'How to protect  $\beta$  cells against ER stress in diabetes?', The 2012 Claes Hellerström Uppsala University - Université Libre de Bruxelles Symposium, February 3, 2012, Uppsala, Sweden
28. 'Endoplasmic reticulum stress and pancreatic  $\beta$  cell demise in type 2 diabetes', Symposium "Cellular Stress, Quality Control and Regeneration in Aging" at the University of Giessen, February 16, 2012, Giessen, Germany
29. 'The role of endoplasmic reticulum stress in pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes', March 1, 2012, University of Geneva, Geneva, Switzerland
30. 'Lipotoxic endoplasmic reticulum stress in pancreatic  $\beta$  cells', British Society for Endocrinology, March 19-22, 2012, Harrogate, UK
31. 'The DNA methylome and transcriptome of human islets in health and disease', 48<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes, October 1-5, 2012, Berlin, Germany
32. 'ER stress and markers of aging in  $\alpha$  and  $\beta$  cells', European Association for the Study of Diabetes - Islet Study Group annual meeting, October 5-7, 2012, Rostock, Germany
33. 'Mechanisms of pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes', November 21, 2012, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
34. 'Epigenetics and diabetes', Annual Congress of the Société Francophone du Diabète, March 26-29, 2013 Montpellier, France
35. 'Mechanisms of  $\beta$  cell failure in type 2 diabetes', European Society for Endocrinology, April 27-May 1, 2013, Copenhagen, Denmark
36. 'Mitochondrial dysfunction in insulin resistance and pancreatic  $\beta$  cell failure: role in the pathogenesis of diabetes in Friedreich ataxia', European Foundation for the Study of Diabetes/Lilly Symposium May 2-3, 2013, Bad Homburg, Germany
37. 'RNA-seq of human islets to study mechanisms of lipotoxic  $\beta$  cell dysfunction and death', May 17, 2013, European Genomic Institute for Diabetes, Lille University, Lille, France
38. 'Glucose metabolism in Friedreich's ataxia', Friedreich's Ataxia Clinical Research Conference, June 6-7, 2013, Silver Spring, USA
39. 'Mechanisms of pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes', August 14, 2013, Symposium 'Nutrients and genetic cues and the function/survival of energy responsive cells', Institute of Biological Sciences, University of Sao Paulo (USP), Sao Paulo, Brazil
40. 'RNA-seq of human islets to study mechanisms of lipotoxic  $\beta$  cell dysfunction and death', August 15, 2013, the Biology Institute of the University of Campinas, Brazil
41. 'The heart of the matter:  $\beta$  cells in diabetes', Oskar Minkowski Prize lecture at the 49<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes, September 23-27, 2013, Barcelona, Spain

42. 'Mechanisms of pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes', November 22, 2013, Miguel Hernández University Elche, Elche, Spain
43. 'Mechanisms of  $\beta$  cell dysfunction and death in type 2 diabetes', Symposium "Brown fat and  $\beta$  cells: examining inter-organ crosstalk and cellular dysfunction in metabolic disease", December 10, 2013, Cambridge, UK
44. 'Molecular mechanisms of  $\beta$  cell demise in type 2 diabetes', Symposium 'Type 2 diabetes and  $\beta$  cells' of the Société Francophone du Diabète, December 13, 2013, Paris, France
45. 'Mechanisms of pancreatic  $\beta$  cell dysfunction and death in type 2 diabetes', Annual Diabetes Research Meeting, Royal College of Surgeons, January 17, 2014, Dublin, Ireland
46. 'The life and times of pancreatic  $\beta$  cells in diabetes', Symposium "New trends in prevention of atherosclerosis" of the Slovak Association of Atherosclerosis, February 20, 2014, Bratislava, Slovakia
47. 'Life and death of pancreatic  $\beta$  cells in diabetes', Auguste Loubatières Prize lecture at the annual congress of the Société Francophone du Diabète, March 13, 2014, Paris, France
48. 'The heart of the matter:  $\beta$  cells in diabetes', Karolinska Institute, March 20, 2014, Stockholm, Sweden
49. 'The heart of the matter:  $\beta$  cells in diabetes', Symposium "Stars from the sky and feet on the ground", May 31, 2014, Portoroz, Slovenia
50. 'Molecular pathways of pancreatic  $\beta$  cell failure in the pathogenesis of different types of diabetes', 2<sup>nd</sup> Best of European Association for the Study of Diabetes India Course, June 1, 2014, Portoroz, Slovenia
51. 'Molecular mechanisms of lipotoxicity and  $\beta$  cell apoptosis in type 2 diabetes', Annual Diabetes Research Meeting, June 19, 2014, Catania, Italy
52. 'Molecular mechanisms of  $\beta$  cell demise in type 2 diabetes', Imperial College London, June 24, 2014, London, UK
53. 'Can we limit the long-term decline of  $\beta$  cells in type 2 diabetes? Mechanisms of  $\beta$  cell failure', Best of American Diabetes Association 2014, June 28, 2014, Madrid, Spain
54. 'Common mechanisms of  $\beta$  cell failure in monogenic and type 2 diabetes', Diabetes Symposium, Tongji Hospital, Huazhong University of Science and Technology, August 7, 2014, Wuhan, China
55. 'Chronicle of an announced death:  $\beta$  cell failure in diabetes', Brazilian Congress of Endocrinology, September 5-9, 2014, Curitiba, Brazil
56. 'The life and times of pancreatic  $\beta$  cells in diabetes', Conference of the Centre Européen pour la Nutrition & la Santé, University of Lyon, November 20, 2014, Lyon, France
57. 'Molecular mechanisms of lipotoxicity and  $\beta$  cell demise in type 2 diabetes', Symposium " $\beta$  cells and adipose tissue - partners in crime for the development of type 2 diabetes", December 12, 2014, Malmö, Sweden
58. 'Molecular mechanisms of  $\beta$  cell demise in type 2 diabetes', Beta Cell Workshop - European Association for the Study of Diabetes - Islet Study Group joint meeting, May 3-7, 2015, Jerusalem, Israel
59. 'Organelle dysfunction in  $\beta$  cells and human diabetes', European Association for the Study of Diabetes - Study Group on Genetics of Diabetes 5<sup>th</sup> meeting, May 7-9, 2015, Krakow, Poland
60. 'Endoplasmic reticulum stress and  $\beta$  cell failure in diabetes', Academy of Finland Center of Excellence on Molecular Systems Immunology and Physiology Research, August 13-14, 2015, Helsinki, Finland
61. 'Endoplasmic reticulum stress and  $\beta$  cell failure in type 2 diabetes and monogenic forms of diabetes', August 24, 2015, the Biology Institute of the University of Campinas, Brazil
62. 'A choice of death:  $\beta$  cell failure in diabetes', 23<sup>rd</sup> Congress of the International Union of Biochemistry and Molecular Biology and 44<sup>th</sup> Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology, August 24-28, 2015, Foz do Iguaçu, Brazil
63. 'Inter-organ and inter-organelle crosstalk in type 2 diabetes', European Genomic Institute for Diabetes school, September 30-October 2, 2015, Béthune, France
64. 'Organelle dysfunction in pancreatic  $\beta$  cells and type 2 diabetes', University of Cambridge, November 12-13, 2015, Cambridge, UK
65. 'Mitochondrial dysfunction and the  $\beta$ -cell', International Diabetes Federation World Diabetes Congress 2015, November 30-December 4, 2015, Vancouver, Canada

66. 'Organelle dysfunction in pancreatic  $\beta$  cells as a cause for monogenic and polygenic forms of diabetes', University of Parma, March 4, 2016, Parma, Italy
67. 'Role and mechanisms of pancreatic  $\beta$  cell dysfunction and apoptosis in the pathogenesis of diabetes', Hvidovre symposium, March 9-11, 2016, Copenhagen, Denmark
68. 'Mechanisms of pancreatic  $\beta$  cell death in type 2 diabetes', Joint Keystone Symposia on Islet Biology: From Cell Birth to Death/Stem Cells and Regeneration in the Digestive Organs, March 13-18, 2016, Keystone, Colorado, USA
69. 'Molecular mechanisms of  $\beta$  cell failure in type 2 diabetes', National Congress of the Spanish Diabetes Society, April 20-22, 2016, Bilbao, Spain
70. 'Lipotoxicity and organ damage:  $\beta$ -cells', National Congress of the Italian Society of Diabetology, May 4-7, 2016, Rimini, Italy
71. 'Organelle dysfunction in  $\beta$  cells and diabetes', the 2016 Claes Hellerström Uppsala University - Université Libre de Bruxelles Symposium, May 18, 2016, Uppsala, Sweden
72. 'Role and mechanisms of pancreatic  $\beta$  cell dysfunction and apoptosis in the pathogenesis of diabetes', Hvidovre symposium, May 18-20, 2016, Copenhagen, Denmark
73. 'Epigenetics and diabetes', 38<sup>th</sup> ESPEN Congress, September 17–20, 2016, Copenhagen, Denmark
74. 'Monogenic diabetes as models of  $\beta$  cell organelle dysfunction in type 2 diabetes', European Association for the Study of Diabetes - Islet Study Group - Beta Cell Workshop joint meeting, May 7-10, 2017, Dresden, Germany
75. 'Using functional genomics to identify mechanisms of  $\beta$  cell dysfunction in diabetes', 38<sup>th</sup> World Congress of the International Union of Physiological Sciences (IUPS), August 1-5, 2017, Rio de Janeiro, Brazil
76. 'Saving pancreatic  $\beta$  cells from cell death in type 2 diabetes', 5<sup>th</sup> Gifu Innovation Lecture International Symposium 'Towards innovative treatment and drug development for diabetes mellitus: from bench to bedside', Gifu Pharmaceutical University, Gifu, Japan, September 22, 2017
77. 'Monogenic forms of diabetes as models of  $\beta$  cell organelle dysfunction in type 2 diabetes' Singapore Symposium on Metabolic Diseases, November 16-17, 2017, Biopolis of Singapore, Singapore
78. 'Organelle dysfunction in pancreatic  $\beta$  cells: lessons learned from monogenic forms of diabetes', European Foundation for the Study of Diabetes/Lilly Symposium February 21-22, 2018, Bad Homburg, Germany
79. 'Organelle dysfunction in pancreatic  $\beta$  cells in type 2 diabetes: lessons learned from monogenic forms of diabetes', D-CURE Symposium 'Frontiers in Diabetes Research', May 2, 2018, Herzliya, Israel
80. 'Endoplasmic reticulum stress: the Achilles heel of pancreatic  $\beta$  cells', Seminar Series of the Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), June 8, 2018, Sevilla, Spain
81. 'Monogenic diabetes as models of  $\beta$  cell organelle dysfunction in type 2 diabetes', 13<sup>th</sup> Congress of the Central European Diabetes Association/33<sup>rd</sup> International Danube Symposium, June 14-16, 2018, Krakow, Poland
82. 'tRNA hypomethylation: a novel mechanism of  $\beta$  cell demise in diabetes', 78<sup>th</sup> Scientific Sessions of the American Diabetes Association, June 22-26, 2018, Orlando, FL, USA

#### National lectures

1. 'Novelties in the prevention and treatment of type 2 diabetes', February 1, 2003, Medical Association of Charleroi, Charleroi
2. 'The metabolic syndrome', February 18, 2004, Division of Gastroenterology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
3. 'The metabolic syndrome', April 24, 2004, Division of Cardiology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
4. 'Progressive loss of  $\beta$ -cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes', 2004 Belgian Endocrine Society annual meeting, Brussels,
5. 'Metabolic characteristics of patients before and after gastroplasty', January 18, 2005, Division of Gastroenterology, Erasmus Hospital, Université Libre de Bruxelles, Brussels

6. 'The metabolic syndrome', January 22, 2005, Department of Internal Medicine, University Hospital, Université Catholique de Louvain, Brussels
7. 'The metabolic syndrome', February 25, 2005, Grand Rounds of Internal Medicine, Bordet University Hospital, Brussels
8. 'The role of body fat distribution in the pathogenesis of type 2 diabetes: from bedside to bench', March 31, 2005, Doctoral School of the Faculty of Medicine, Université Libre de Bruxelles, Brussels
9. 'Metabolic characteristics of patients before and after gastroplasty', September 23, 2005, Department of Surgery, St Pierre Hospital, Université Libre de Bruxelles, Brussels
10. 'Endocrine changes in patients with anorexia nervosa', May 4, 2006, Department of Psychiatry, Erasmus Hospital, Université Libre de Bruxelles, Brussels
11. 'Obesity – a medical viewpoint', May 10, 2006, Department of Surgery, Hospital of Ixelles, Brussels
12. 'Obesity and gastroplasty', June 22, 2006, Department of Psychiatry, Erasmus Hospital, Université Libre de Bruxelles, Brussels
13. 'Treatment of the metabolic syndrome', November 22, 2006, Division of Gastroenterology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
14. 'Physical activity for the prevention and treatment of type 2 diabetes', January 30, 2007, Department of Physiotherapy, Erasmus Hospital, Université Libre de Bruxelles, Brussels
15. 'β-Cell loss in type 2 diabetes: the role of lipotoxicity and endoplasmic reticulum stress' February 1, 2007, Division of Endocrinology, Katholieke Universiteit Leuven, Leuven
16. 'New medical, surgical and endoscopic treatment options for obesity', October 13, 2007, Meeting of the Royal Belgian Society for Gastroenterology, Brussels
17. 'Medical treatment of obesity', November 21, 2007, Division of Gastroenterology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
18. 'The β-cell under metabolic attack', October 11, 2008, Update on Diabetes meeting, Brussels
19. 'Free fatty acids contribute to nutrient- and obesity-induced β-cell loss in type 2 diabetes via induction of endoplasmic reticulum stress', October 14, 2008, Belgian Lipid Club, Brussels
20. 'The metabolic syndrome', December 6, 2008, Obesity Clinic, Edith Cavell Hospital, Brussels
21. 'Pathogenesis of obesity and type 2 diabetes', April 2, 2009, Department of Physiotherapy, Erasmus Hospital, Université Libre de Bruxelles, Brussels
22. 'Pathophysiology of type 1 diabetes and therapeutic implications', January 29, 2010, Postgraduate interuniversity course in endocrinology, Université Catholique de Louvain, Brussels
23. 'Physical activity in the treatment of diabetes', February 23, 2010, Department of Physiotherapy, Erasmus Hospital, Université Libre de Bruxelles, Brussels
24. 'Stress in the ER (endoplasmic reticulum) and the development of diabetes', October 23, 2010, Annual Meeting of the Belgian Endocrine Society, Brussels
25. 'The obesity platform', February 9, 2011, Division of Gastroenterology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
26. 'The obesity platform', May 30, 2011, Division of Cardiology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
27. 'The obesity platform', October 28, 2011, Division of Gynecology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
28. 'Central role and mechanisms of pancreatic β cell dysfunction in type 2 diabetes', December 3, 2012, International Diabetes Lecture series 2012 at Gasthuisberg, Katholieke Universiteit Leuven, Leuven
29. 'Physical activity in the treatment of diabetes and obesity', March 14, 2013, Department of Physiotherapy, Erasmus Hospital, Université Libre de Bruxelles, Brussels
30. 'A longstanding case of unexplained hypoglycemia', May 28, 2013, Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
31. 'Importance and challenges of physical rehabilitation in obesity and type 2 diabetes', September 14, 2013, Physical rehabilitation congress, Brussels
32. 'The heart of the matter: β cells in diabetes', February 10, 2014, Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels

33. 'Epigenetics and type 2 diabetes', February 15, 2014, Annual Meeting of the Belgian Association for the Study of Obesity, Brussels
34. ' $\beta$  Cell apoptosis: key to diabetes development?' February 28, 2014, Department of Internal Medicine, Erasmus Hospital, Université Libre de Bruxelles, Brussels
35. 'Epigenetic dysregulation of pancreatic endocrine function in type 2 diabetes', April 25, 2014, Annual Meeting of the Belgian Nutrition Society, Brussels
36. 'Men and obesity', May 1, 2014, 6<sup>th</sup> Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, Brussels
37. 'The heart of the matter:  $\beta$  cells in diabetes', May 17, 2014, Novartis National Diabetes Symposium, Brussels
38. 'Common mechanisms of  $\beta$  cell failure in monogenic and type 2 diabetes', June 6, 2014, opening symposium of the ULB Center for Diabetes Research, Brussels
39. 'Life and death of pancreatic  $\beta$  cells in diabetes', June 12, 2014, Doctoral School of the Faculty of Medicine, Université Libre de Bruxelles, Brussels
40. 'A novel type of diabetes due to a missense mutation in *PPP1R15B*', September 8, 2015, Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
41. 'Mechanisms of metabolic stress-induced  $\beta$  cell death in diabetes', February 26, 2016, Opening Symposium of the Brussels Diabetes Research Pole, at the Université Libre de Bruxelles, Brussels
42. 'The endocrine pancreas in diabetes: a story of hyperbolae', March 20, 2017, Closed-format meeting on glucose control in the intensive care unit, Brussels
43. 'Precision medicine in diabetes: clinical interest of an etiology-based diagnosis', March 20, 2017, Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
44. 'Cholesterol carriers in all their forms: how dangerous are they?', October 21, 2017, Department of Cardiology, Erasmus Hospital, Université Libre de Bruxelles, Brussels
45. 'Research approaches to understand and cure pancreatic  $\beta$  cell failure in diabetes', November 14, 2017, European Medical Students' Association Antwerpen Symposium, Antwerp University, Antwerp
46. 'Beyond type 1 and type 2 diabetes: lessons learned from monogenic forms of diabetes', March 23, 2018, Diabetes Clinic, University Hospital Vrije Universiteit Brussel, Brussels
47. 'Type 2 diabetes', June 4-5, 2018, *f*-TALES workshop 'A roadmap towards diabetes treatment: to the  $\beta$  cell and beyond', Brussels
48. 'Precision medicine in diabetes', January 18, 2019, Research Lectures of the Erasmus Hospital, Université Libre de Bruxelles, Brussels

#### Lectures to lay people and interviews

1. 'Obesity: body weight and glands', special encyclopedia issue of the newspaper Le Soir, September 30, 2008, Belgium
2. 'Relative contribution of abnormal insulin secretion and insulin action in the development of diabetes in Friedreich ataxia', March 21, 2009, Annual meeting of the French Association of Friedreich Ataxia, Nouan-Le-Fuzelier, France
3. 'Life and death of the  $\beta$  cell', May 21, 2011, 4<sup>th</sup> Belgian Diabetes Fair organized by the Belgian Diabetes Association, Brussels Expo, Brussels, Belgium
4. 'Are extreme leanness and obesity genetic disorders?', interview for the news of the Belgian television RTBF, October 10, 2011, Belgium
5. 'New insights into diabetes associated with Friedreich ataxia', report published in December, 2012, in the medical newspaper Vessels, Heart, Lungs, Belgium
6. 'A better understanding of diabetes related to Friedreich ataxia may open new therapeutic opportunities for this neurodegenerative disease', interview published on January 15, 2013, in the medical newspaper Neuron, Belgium
7. 'Understanding diabetes related to Friedreich ataxia', interview published on January 30, 2013, in the medical newspaper The Specialist, Belgium
8. 'Is obesity in Belgium an underestimated problem?', online chat for the French-speaking Belgian Radio and Television (RTBF), May 15, 2013, Belgium
9. 'Belgian diabetes research awarded', interview published in the November-December issue of the journal of the Belgian Diabetes Association, 2013, Belgium
10. 'The  $\beta$  cell under the loupe', interview published in September, 2014, in the medical newspaper Vessels, Heart, Lungs, Belgium

11. 'A new anti-obesity molecule', interview published in the newspaper *Le Soir*, May 21, 2014, Belgium
12. 'Diabetes: Brussels central hub of research' on the creation of the ULB Center for Diabetes Research, *Daily Science*, June 10, 2014, Belgium
13. 'When diabetes is part of the picture...', interview published in the magazine *Femmes d'Aujourd'hui*, 2015, Belgium
14. 'The ULB tests a revolutionary treatment of diabetes', interview published in the newspaper *Le Soir*, July 30, 2015, Belgium
15. 'Duodenal mucosal resurfacing, a new approach for type 2 diabetes', interview published in September, 2015, in the medical newspaper *Vessels, Heart, Lungs*, Belgium
16. 'Unveiling mechanisms underlying type 2 diabetes', interview published in the newspaper *De Morgen*, May 11, 2016, Belgium
17. 'Discovery of a novel method to restore insulin-producing cells', interview for the news of the Belgian television *RTL-TVi*, December 5, 2016, Belgium
18. 'A new type of diabetes has been identified', interview published in November, 2017, in the medical newspapers *Le Journal du Médecin* and *Artsenkrant*, Belgium
19. 'The new era of precision medicine in diabetes: the case of RFX6 diabetes', published in February, 2018, in the medical newspaper *Vessels, Heart, Lungs*, Belgium

#### *ACTIVITIES AS REFEREE*

Reviewer ad hoc for scientific journals:

Acta Clinica Belgica  
American Journal of Physiology - Cell Physiology  
American Journal of Physiology - Endocrinology and Metabolism  
Archives of Medical Research  
Biochemical Journal  
Biochemical Pharmacology  
Biochemistry  
BMC Cell Biology  
BMC Research Notes  
British Journal of Pharmacology  
Cell Death & Differentiation  
Cell Metabolism  
Cell & Tissue Research  
Clinical Science  
Developmental Cell  
Diabetes  
Diabetes Care  
Diabetes & Metabolism  
Diabetic Medicine  
Diabetologia  
Disease Models & Mechanisms  
The EMBO Journal  
European Journal of Endocrinology  
European Journal of Pharmacology  
FEBS Journal  
FEBS Letters  
FEMS Yeast Research  
Future Cardiology  
Future Lipidology  
Gynecological Endocrinology  
Heredity  
Hormone and Metabolic Research  
Human Molecular Genetics  
International Immunopharmacology  
Journal of the American College of Nutrition  
Journal of Biological Chemistry  
Journal of Clinical Endocrinology and Metabolism

Journal of Endocrinology  
Journal of Medical Genetics  
Journal of Molecular Endocrinology  
Journal of Molecular Medicine  
Journal of the Neurological Sciences  
Medical Science Monitor  
Molecular and Cellular Endocrinology  
Molecular Metabolism  
Nature Communications  
Nature Reviews Endocrinology  
Obesity  
Obesity Research  
Physiological Research  
PLoS ONE  
Preventive Medicine  
Trends in Endocrinology and Metabolism

Reviewer ad hoc for funding agencies and universities:

Association syndrome de Wolfram, Eye Hope Foundation and Snow Foundation (2017)  
ATIP-Avenir call of the CNRS and Inserm, France (2015)  
Lise Meitner-Program of the Austrian Science Fund (FWF), Austria (2013)  
Member of the Scientific Committee of the Brugmann Foundation, Brussels, Belgium (2014-2019)  
Concerted Research Actions Academy of Louvain Universities, Brussels, Belgium (2012)  
Czech Science Foundation (2009)  
Diabetes UK (2008, 2012, 2016)  
Diabetes Wellness Network Sverige, Diabetes Research & Wellness Foundation (2013)  
Dutch Diabetes Research Foundation (2007, 2009)  
Erasmus Hospital Medical Council, Université Libre de Bruxelles, Brussels, Belgium (2016)  
European Foundation for the Study of Diabetes (EFSD): EFSD CDS Lilly (2008), EFSD New Horizons (2009), EFSD Amylin (2010, 2011), EFSD Boehringer Ingelheim (2013), Novo Nordisk (2017)  
European Research Council (ERC) Starting grants (2016)  
European Union Horizon 2020 PHC 10 - 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms (2014)  
European Union Horizon 2020 PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities (2014, 2015)  
European Union Horizon 2020 Personalized Medicine SC1-PM-09 - 2016: New therapies for chronic diseases (2016)  
French Diabetes Research Foundation (Fondation Francophone pour la Recherche sur le Diabète) (2013-2016)  
French Diabetes Society (Société Francophone du Diabète) (2015-2017)  
French Foundation for Rare Diseases (2016)  
EXODIAB Swedish Strategic Research Area (2013)  
Fondation pour la Recherche Médicale, France (2010)  
AERES External Review committee of the Laboratory of Philippe Froguel, Lille University, France (2013)  
Health Research Board Ireland (2006)  
Hungarian Scientific Research Fund (OTKA), Hungary (2012)  
Israel Science Foundation (2008, 2011, 2013)  
Israel Science Foundation – Juvenile Diabetes Research Foundation Program in Type 1 Diabetes Research (2012)  
Italian Diabetes Society (2007)  
IWT - the agency for Innovation by Science and Technology, Belgium (2015)  
Kentucky Science and Engineering Foundation (KSEF), USA (2015)  
Lille University Hospital and University Lille 2, France (2017)  
Ministry of Science, Israel (2008)  
Novo Nordisk UK Research Foundation, UK (2012)  
Pasteur Institute of Lille - Center for Transdisciplinary Research on Longevity (2017)  
Research Grants Council of Hong Kong (2013)  
Swiss National Science Foundation (2011, 2012)



Toronto General Hospital Research Institute, Canada (2011)  
University of Antwerp, Belgium (2013, 2015)  
University of Groningen, the Netherlands (2013)  
University of Michigan Regional Comprehensive Metabolomics Resource Core (2016)  
University of Toronto, Canada (2011)  
Washington University, Saint Louis, MO, USA (2011, 2016)  
The Wellcome Trust, UK (2014)  
Willy Gepts Research Foundation, Vrije Universiteit Brussel, Brussels, Belgium (2010)

Reviewer of scientific awards:

Albert Renold Prize Committee of the European Association for the Study of Diabetes (2013-2015)  
Rising Star Prize Committee of the European Association for the Study of Diabetes (2014-2016)  
Belgian Novo Nordisk Prize in Diabetology (2014-present)  
Belgian AstraZeneca Award in Diabetes (2015)  
The Academy of Medical Sciences, UK (2016)

*MEMBERSHIP OF EDITORIAL BOARDS OF SCIENTIFIC JOURNALS*

Associate Editor of *Diabetologia* [Impact Factor 6.4] (2006-2009)  
Member of Advisory Board of *Diabetologia* (2010-2013)  
Member of Advisory Board of *The Lancet Diabetes & Endocrinology* (2013-2015)

*MEMBERSHIP OF BOARDS OF SCIENTIFIC SOCIETIES*

Secretary of the Islet Study Group of the European Association for the Study of Diabetes (2012-2013)  
President of the Islet Study Group of the European Association for the Study of Diabetes (2013-2015)  
Member of the Scientific Council of the French Diabetes Research Foundation (Fondation Francophone pour la Recherche sur le Diabète) (2013-2016)  
Member of the Scientific Board of the French Diabetes Society (Société Francophone du Diabète) (2014-2017)

*PARTICIPATION IN THE ORGANIZATION OF SCIENTIFIC MEETINGS*

Organizing Committee of the European Association for the Study of Diabetes Islet Study Group Symposium 2007, September 21-23, Brussels, Belgium  
Abstract Review Committee of the International Diabetes Federation's 20<sup>th</sup> World Diabetes Congress 2009, October 18-22, Montreal, Canada  
Scientific Advisory Committee of the European Association for the Study of Diabetes Islet Study Group Symposium 2013, September 27-29, Sitges, Spain  
Scientific Programme Committee of the 50<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes 2014, September 15-19, Vienna, Austria  
Scientific Programme Committee of the French Diabetes Society (Société Francophone du Diabète) 2015, March 24-27, Bordeaux, France  
Organizing Committee of the European Association for the Study of Diabetes Islet Study Group Symposium 2015, May 3-7, Jerusalem, Israel  
Organizing Committee of the International Diabetes Federation's 20<sup>th</sup> World Diabetes Congress 2015, November 30-December 4, Vancouver, Canada  
Scientific Programme Committee of the French Diabetes Society (Société Francophone du Diabète) 2016, March 22-25, Lyon, France  
Scientific Programme Committee of the French Diabetes Society (Société Francophone du Diabète) 2017, March 28-31, Lille, France

Abstract Review Committee of the 54<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes 2018, October 1-5, Berlin, Germany

*MEMBERSHIP OF NATIONAL ACADEMIC BOARDS, COMMITTEES AND ACADEMIES*

Committee for deontology and research integrity of the Université Libre de Bruxelles (2013-2019)

National committee for the training and certification in Endocrinology - Diabetology (2015-present)

Associate Member of the Royal Academy of Medicine of Belgium (2017-present)

*PARTICIPATION IN INTERNATIONAL COMMITTEES*

Chair of the European Association for the Study of Diabetes (EASD) European Union Committee, that aims to increase EU funding for research and public health related to diabetes (2015-2017)

*SCIENTIFIC ADVISORY BOARD OF RESEARCH CENTERS*

Obesity and Co-Morbidity Research Center, State of São Paulo Foundation for Research (FAPESP), Brazil (2013-present)

Cordeliers Research Center, Paris, France (2014-2017)

*CITATIONS OF PUBLICATIONS*

Listed among the top 1% of authors in terms of total citations over the past 10 years (Essential Science Indicators, ISI Web of Knowledge)

Average NIH Relative Citation Ratio (RCR): 6.2, i.e. the publications generate 6.2-fold as many citations/year as the average NIH-funded paper in this field (Hutchins BI et al. Relative Citation Ratio (RCR): A new metric that uses citation rates to measure influence at the article level, PLoS Biol 2016).


Sum of the weighted RCR: 446

Scopus, February 2018

Sum of the times cited: 8303

Average citations per paper: 95

H-index: 39



*LIST OF PUBLICATIONS*

Original papers

1. Gruppung A, Cnop M, Van Schravendijk C, Hannaert JC, Van Berkel T and Pipeleers D. Low density lipoprotein binding and uptake by human and rat islet  $\beta$  cells. *Endocrinology* 1997, 138:4064-4068. [Impact Factor (IF) 4.348; RCR 1.09]
2. Cnop M, Gruppung A, Hoorens A, Bouwens L, Marichal M and Pipeleers D. Endocytosis of low density lipoprotein by human pancreatic  $\beta$  cells and uptake in lipid-storing vesicles, which increase with age. *Am J Pathol* 2000, 156:237-244. [IF 6.971; RCR 0.79]
3. Cnop M, Hannaert JC, Hoorens A, Eizirik DL and Pipeleers D. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. *Diabetes* 2001, 50:1771-1777. [IF 7.700; RCR 8.59]
4. Wang F, Hull RL, Vidal J, Cnop M and Kahn SE. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. *Diabetes* 2001, 50:2514-2520. [IF 7.700; RCR 0.99]
5. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH and Kahn SE. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. *Diabetes* 2002, 51:1005-1015. [IF 8.256; RCR 6.89]
6. Cnop M, Hannaert JC and Pipeleers D. Troglitazone does not protect rat pancreatic  $\beta$  cells against free fatty acid-induced cytotoxicity. *Biochem Pharmacol* 2002, 63:1281-1285. [IF 3.542; RCR 0.75]
7. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID Study Group.  $\beta$  cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. *Diabetes* 2002, 51:2170-2178. [IF 8.256; RCR 4.91]
8. Cnop M, Hannaert JC, Gruppung A and Pipeleers D. Low density lipoprotein can cause death of islet  $\beta$  cells by its cellular uptake and oxidative modification. *Endocrinology* 2002, 143:3449-3453. [IF 5.095; RCR 1.54]
9. Nieves DJ\*, Cnop M\*, Retzlaff B, Walden CE, Brunzell JD, Knopp RH and Kahn SE. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat deposition. *Diabetes* 2003, 52:172-179. [IF 8.298; RCR 4.35] \*shared first authorship.
10. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL and Kahn SE. Increased dietary fat promotes islet amyloid formation and  $\beta$ -cell secretory dysfunction. *Diabetes* 2003, 52:372-379. [IF 8.298; RCR 1.75]
11. Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A and Kahn SE. The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. *Diabetologia* 2003, 46:71-79. [IF 5.689; RCR 0.51]
12. Cnop M, Havel PJ, Utschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD and Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 2003, 46:459-469. [IF 5.689; RCR 24.16]
13. Kharroubi I, Rasschaert J, Eizirik DL and Cnop M. Expression of adiponectin receptors in pancreatic  $\beta$  cells. *Biochem Biophys Res Comm* 2003, 312:1118-1122. [IF 2.836; RCR 4.17]
14. Kharroubi I, Ladrière L, Cardozo AK, Dogusan Z, Cnop M and Eizirik DL. Free fatty acids and cytokines induce pancreatic  $\beta$  cell apoptosis by different mechanisms: role of NF- $\kappa$ B and endoplasmic reticulum stress. *Endocrinology* 2004, 145:5087-5096. [IF 5.151; RCR 9.63]
15. Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P and Eizirik DL. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type

- 2 diabetes milieu to human pancreatic islets? *Diabetes* 2005, 54:3238-3244. [IF 8.028; RCR 2.02]
16. Kharroubi I, Lee C-H, Hekerman P, Darville M, Evans R, Eizirik DL and Cnop M. BCL-6: a possible missing link for anti-inflammatory PPAR- $\delta$  signalling in pancreatic beta cells. *Diabetologia* 2006, 49:2350-2358. [IF 5.247; RCR 0.71]
  17. Cnop M, Ladrière L, Hekerman P, Ortis F, Cardozo AK, Dogusan Z, Flamez D, Boyce M, Yuan J and Eizirik DL. Selective inhibition of eIF2 $\alpha$  dephosphorylation potentiates fatty acid-induced ER stress and causes pancreatic  $\beta$ -cell dysfunction and apoptosis. *J Biol Chem* 2007, 282:3989-3997. [IF 5.581; RCR 5.51]
  18. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY and Kahn SE. Progressive loss of  $\beta$ -cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. *Diabetes Care* 2007, 30:677-682. [IF 7.851; RCR 2.66]
  19. Pirot P, Ortis F, Cnop M, Ma Y, Hendershot LM, Eizirik DL and Cardozo AK. Transcriptional regulation of the endoplasmic reticulum stress gene Chop in pancreatic insulin producing cells. *Diabetes* 2007, 56:1069-1077. [IF 8.261; RCR 1.93]
  20. Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M, Boggi U, Filipponi F, Weir GC, Eizirik DL and Cnop M. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. *Diabetologia* 2007, 50:2486-2494. [IF 5.822; RCR 6.33]
  21. Guri AJ, Hontecillas R, Ferrer G, Casagran O, Wankhade U, Noble AM, Eizirik DL, Ortis F, Cnop M, Liu D, Si H and Bassaganya-Riera J. Loss of PPAR $\gamma$  in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. *J Nutr Biochem* 2008, 19:216-228. [IF 4.352; RCR 1.32]
  22. Cunha DA, Hekerman P, Ladrière L, Bazarra-Castro A, Ortis F, Wakeham MC, Moore F, Rasschaert J, Cardozo AK, Bellomo E, Overbergh L, Mathieu C, Lupi R, Hai T, Herchuelz A, Marchetti P, Rutter GA, Eizirik DL and Cnop M. Initiation and execution of lipotoxic ER stress in pancreatic beta cells. *J Cell Sci* 2008, 121:2308-2318. [IF 6.247; RCR 8.81]
  23. Moore F, Colli ML, Cnop M, Igoillo-Esteve M, Cardozo AK, Cunha DA, Bugliani M, Marchetti P and Eizirik DL. PTPN2, a candidate gene for type 1 diabetes, modulates interferon- $\gamma$ -induced pancreatic  $\beta$ -cell apoptosis. *Diabetes* 2009, 58:1283-1291. [IF 8.505; RCR 2.47]
  24. Coppola G, Marmolino D, Acquaviva F, Wang Q, Lu D, Rai M, Cnop M, Coccozza S, Pandolfo M and Geschwind DH. Functional genomic analysis of frataxin deficiency identifies the PPAR $\gamma$  pathway as a novel therapeutic target in Friedreich's ataxia. *Hum Mol Genet* 2009, 18:2452-2461. [IF 7.386; RCR 1.86]
  25. Li N, Brun T, Cnop M, Cunha DA, Eizirik DL and Maechler P. Transient oxidative stress damages mitochondrial machinery inducing persistent  $\beta$ -cell dysfunction. *J Biol Chem* 2009, 284:23602-23612. [IF 5.328; RCR 1.91]
  26. Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL and Cnop M. Glucagon-like peptide-1 agonists protect pancreatic  $\beta$ -cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. *Diabetes* 2009, 58:2851-2862. [IF 8.505; RCR 3.74]
  27. Martinovici D, Ransy V, Vanden Eijnden S, Ridremont C, Pardou A, Cassart M, Avni F, Donner C, Lingier P, Mathieu A, Gulbis B, De Brouckère V, Cnop M, Abramowicz M and Désir J. Neonatal hemochromatosis and Martinez-Frias syndrome of intestinal atresia and diabetes mellitus in a consanguineous newborn. *Eur J Med Genet* 2010, 53:25-28. [IF 2.335; RCR 0.59]
  28. Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa MB, Sayyed F, van de Laar L, Gunter JH, de Koning EJP, Walls GV, Gray DWG, Johnson PRV, Hansen BC, Morris JF, Pipeleers-Marichal M, Cnop I and Clark A. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. *Diabetologia* 2010, 53:321-330. [IF 6.973; RCR 3.53]

29. Ladrière L, Igoillo-Esteve M, Cunha DA, Brion JP, Bugliani M, Marchetti P, Eizirik DL and Cnop M. Enhanced signaling downstream of ribonucleic acid-activated protein kinase-like endoplasmic reticulum kinase potentiates lipotoxic endoplasmic reticulum stress in human islets. *J Clin Endocrinol Metab* 2010, 95:1442-1449. [IF 6.495; RCR 1.33]
30. Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Grieco FA, Dotta F, Weir GC, Marchetti P, Eizirik DL and Cnop M. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. *Diabetologia* 2010, 53:1395-1405. [IF 6.973; RCR 3.74]
31. Maris M, Ferreira GB, D'Hertog W, Cnop M, Waelkens E, Overbergh L and Mathieu C. High glucose induces dysfunction in insulin secretory cells by different pathways: a proteomic approach. *J Proteome Res* 2010, 9:6274-6287. [IF 5.460; RCR 0.88]
32. Igoillo-Esteve M, Gurzov EN, Eizirik DL and Cnop M. The transcription factor BCL-6 modulates pancreatic  $\beta$ -cell inflammatory responses. *Endocrinology* 2011, 152:447-456. [IF 4.459; RCR 0.13]
33. Lemaire K, Moura RF, Granvik M, Igoillo-Esteve M, Hohmeier HE, Hendrickx N, Newgard CB, Waelkens E, Cnop M and Schuit F. Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis. *PLoS ONE* 2011, 6:e18517. [IF 4.092; RCR 2.11]
34. Maris M, Waelkens E, Cnop M, D'Hertog W, Cunha DA, Korf H, Koike T, Overbergh L and Mathieu C. Oleate-induced beta cell dysfunction and apoptosis: a proteomic approach to glucolipotoxicity by an unsaturated fatty acid. *J Proteome Res* 2011, 10:3372-3385. [IF 5.113; RCR 0.46]
35. Johansson BB, Torsvik J, Bjørkhaug L, Vesterhus M, Ragvin A, Tjora E, Fjeld K, Hoem D, Johansson S, Ræder H, Lindquist S, Hernell O, Cnop M, Saraste J, Flatmark T, Molven A and Njølstad PR. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. *J Biol Chem* 2011, 286:34593-34605. [IF 4.773; RCR 1.30]
36. Vos B, Moreno C, Nagy N, Féry F, Cnop M, Vereerstraeten P, Devière J, Adler M. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. *Acta Gastroenterol Belg* 2011, 74:389-394. [IF 0.638; RCR 1.28]
37. Depreter F, Burniat A, Blocklet D, Lacroix S, Cnop M, Féry F, Van Aelst N, Pilcer G, Deleers M, Goldman S and Amighi K. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. *Eur J Pharm Biopharm* 2012, 80:4-13. [IF 3.826; RCR 1.14]
38. Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Deplus R, Calonne E, Volkmar U, Igoillo-Esteve M, Naamane N, Del Guerra S, Masini M, Bugliani M, Marchetti P, Cnop M, Eizirik DL and Fuks F. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. *EMBO J* 2012, 31:1405-1426. [IF 9.822; RCR 8.66]
39. Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M, Ortis F, Santin I, Colli ML, Barthson J, Bouwens L, Hughes L, Gregory L, Lunter G, Marselli L, Marchetti P, McCarthy MI and Cnop M. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. *PLoS Genet* 2012, 8:e1002552. [IF 8.517; RCR 7.37]
40. Maris M, Overbergh L, Gysemans C, Waget A, Cardozo AK, Verdrengh E, Cunha JPM, Gotoh T, Cnop M, Eizirik DL, Burcelin R and Mathieu C. Deletion of C/EBP homologous protein (Chop) in C57Bl/6 mice dissociates obesity from insulin resistance. *Diabetologia* 2012, 55:1167-1178. [IF 6.487; RCR 1.59]
41. Miani M, Colli ML, Ladrière L, Cnop M and Eizirik DL. Mild endoplasmic reticulum stress augments the pro-inflammatory effect of IL-1 $\beta$  in pancreatic rat  $\beta$ -cells via the IRE1 $\alpha$ /XBP1s pathway. *Endocrinology* 2012, 153:3017-3028. [IF 4.717; RCR 1.29]
42. Cunha DA, Igoillo-Esteve M, Gurzov EN, Germano CM, Naamane N, Marfour I, Fukaya M, Vanderwinden JM, Gysemans C, Mathieu C, Marselli L, Marchetti P, Harding HP, Ron D, Eizirik DL and Cnop M. Death protein 5 and p53-upregulated modulator of apoptosis

- mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human  $\beta$ -cell apoptosis. *Diabetes* 2012, 61:2763-2775. [IF 7.895; RCR 2.73]
43. Cnop M, Igoillo-Esteve M, Rai M, Begu A, Serroukh Y, Depondt C, Musuaya AE, Marhfour I, Ladrière L, Moles Lopez X, Lefkaditis D, Moore F, Brion JP, Cooper JM, Schapira AHV, Clark A, Koeppen AH, Marchetti P, Pandolfo M, Eizirik DL and Féry F. Central role and mechanisms of  $\beta$  cell dysfunction and death in Friedreich ataxia-associated diabetes. *Ann Neurol* 2012, 72:971-982. [IF 11.193; RCR 1.38]
  44. Maris M, Robert S, Waelkens E, Derua R, Hernangomez M, d'Hertog W, Cnop M, Mathieu C and Overbergh L. The role of the saturated non-esterified fatty acid palmitate in beta cell dysfunction. *J Proteome Res* 2013,12:347-362. [IF 5.001; RCR 1.24]
  45. Nogueira TC, Paula FM, Villate O, Colli ML, Moura RF, Cunha DA, Marselli L, Marchetti P, Cnop M, Julier C and Eizirik DL. GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic  $\beta$  cell apoptosis via regulation of a splice variant of the BH3-only protein Bim. *PLoS Genet* 2013, 9:e1003532. [IF 8.167; RCR 2.81]
  46. Miani M, Barthson J, Colli ML, Brozzi F, Cnop M and Eizirik DL. Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1 $\beta$ -induced apoptosis via Bim/A1 imbalance. *Cell Death Dis* 2013, 4:e701. [IF 5.177; RCR 1.11]
  47. Igoillo-Esteve M, Genin A, Lambert N, Desir J, Pirson I, Abdulkarim B, Simonis N, Drielsma A, Marselli L, Marchetti P, Vanderhaeghen P, Eizirik DL, Wuyts W, Julier C, Chakera AJ, Ellard S, Hattersley AT, Abramowicz M and Cnop M. tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans. *PLoS Genet* 2013, 9:e1003888. [IF 8.167; RCR 1.36]
  48. Cnop M, Abdulkarim B, Bottu G, Cunha DA, Igoillo-Esteve M, Masini M, Turatsinze JV, Griebel T, Villate O, Santin I, Bugliani M, Ladriere L, Marselli L, McCarthy MI, Marchetti P, Sammeth M and Eizirik DL. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. *Diabetes* 2014, 63:1978-1993. [IF 8.095; RCR 5.71]
  49. Cunha DA, Gurzov EN, Naamane N, Ortis F, Cardozo AK, Bugliani M, Marchetti P, Eizirik DL and Cnop M. JunB protects  $\beta$ -cells from lipotoxicity via the XBP1-AKT pathway. *Cell Death Differ* 2014, 21:1313-1324. [IF 8.184; RCR 1.10]
  50. Mathijs I, Cunha DA, Himpe E, Ladriere L, Chellan N, Roux RC, Joubert E, Muller C, Cnop M, Louw J and Bouwens L. A phenylpropenoic acid glucoside phytochemical augments pancreatic  $\beta$  cell mass in high-fat diet-fed mice and protects  $\beta$  cells from ER stress-induced apoptosis. *Mol Nutr Food Res* 2014, 58:1980-1990. [IF 4.603; RCR 1.08]
  51. Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB, and the Clinical Management Guidelines Writing Group Balcer L, Bartek R, Bates C, Campagna E, Cnop M, Dürr A, Emmanuel A, Farmer J, Flynn J, Friedman LS, Giunti P, Hadjivassiliou M, Ho M, Isaya G, Kearney M, Loucas M, Marotti C, Milne S, Morlet T, McGarry A, Panicker J, Parkinson M, Payne RM, Peverill R, Rance G, Rodriguez L, Schadt KA, Seyer L, Subramony SH, Sullivan KL, Vogel A, Yiu E, Yoon G, Zesiewicz TA. Clinical management guidelines for Friedreich ataxia. *Orphanet J Rare Dis* 2014, 9:184. [IF 3.358; RCR 1.17]
  52. Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, Marselli L, Marchetti P, Jonas JC, Eizirik DL, Pandolfo M and Cnop M. Unveiling a common mechanism of apoptosis in  $\beta$ -cells and neurons in Friedreich's ataxia. *Hum Mol Genet* 2015, 24:2274-2286. [IF 5.985; RCR 3.06]
  53. Fjeld K, Weiss FU, Lasher D, Rosendahl J, Chen JM, Johansson BB, Kirsten H, Ruffert C, Masson E, Steine SJ, Bugert P, Cnop M, Grützmann R, Mayerle J, Mössner J, Ringdal M, Schulz HU, Sendler M, Simon P, Sztromwasser P, Torsvik J, Scholz M, Tjora E, Férec C, Witt H, Lerch MM, Njølstad PR, Johansson S and Molven A. A recombinant allele of the lipase gene *CEL* and its pseudogene *CELP* confers susceptibility to chronic pancreatitis. *Nat Genet* 2015, 47:518-522. [IF 31.616; RCR 5.17]
  54. Oliveira AF, Cunha DA, Ladriere L, Igoillo-Esteve M, Bugliani M, Marchetti P and Cnop M. In vitro use of free fatty acids bound to albumin: a comparison of protocols. *BioTechniques* 2015, 58:228-233. [IF 2.948; RCR 1.18]

55. Marroqui L, Masini M, Merino B, Grieco FA, Millard I, Dubois C, Quesada I, Marchetti P, Cnop M and Eizirik DL. Pancreatic  $\alpha$  cells are resistant to metabolic stress-induced apoptosis in type 2 diabetes. *EBioMedicine* 2015, 2:378-385. [RCR 2.60]
56. Kyrilli A, Igoillo-Esteve M, Féry F, Grieco FA, Eisendrath P, Blocklet D, Goldman S, Henquin JC, Gotthardt M and Cnop M. Insulinoma localization by glucagon-like peptide-1 receptor imaging after 18 years of hypoglycemia. *AACE Clinical Case Reports* 2015, 1:e187-e193.
57. Abdulkarim B, Nicolino M, Igoillo-Esteve M, Daures M, Romero S, Philippi A, Senée V, Lopes M, Cunha DA, Harding HP, Derbois C, Bendelac N, Hattersley AT, Eizirik DL, Ron D, Cnop M and Julier C. A missense mutation in *PPP1R15B* causes a syndrome including diabetes, short stature and microcephaly. *Diabetes* 2015, 64:3951-3962. [IF 8.095; RCR 1.45]
58. Himpe E, Cunha DA, Song I, Bugliani M, Marchetti P, Cnop M and Bouwens L. Phenylpropenoic acid glucoside from rooibos protects pancreatic  $\beta$  cells against cell death induced by acute injury. *PLoS ONE* 2016, 11: e0157604. [IF 2.806]
59. Cunha DA, Cito M, Carlsson PO, Vanderwinden JM, Molkentin JD, Bugliani M, Marchetti P, Eizirik DL and Cnop M. Thrombospondin 1 protects pancreatic  $\beta$ -cells from lipotoxicity via the PERK-NRF2 pathway. *Cell Death Differ* 2016, 23:1995-2006. [IF 8.339]
60. Boscolo M, Féry F and Cnop M. Beneficial outcomes of sleeve gastrectomy in a morbidly obese patient with Bardet-Biedl syndrome. *J Endocr Soc* 2017, 1:317-322.
61. Abdulkarim B, Hernangomez M, Igoillo-Esteve M, Cunha DA, Marselli L, Marchetti P, Ladriere L and Cnop M. Guanabenz sensitizes pancreatic  $\beta$  cells to lipotoxic endoplasmic reticulum stress and apoptosis. *Endocrinology* 2017, 158:1659-1670.
62. Lee SH, Cunha DA, Piermarocchi C, Paternostro G, Pinkerton A, Ladriere L, Marchetti P, Eizirik DL, Cnop M and Levine F. High-throughput screening and bioinformatic analysis to ascertain compounds that prevent saturated fatty acid-induced  $\beta$ -cell apoptosis. *Biochem Pharmacol* 2017, 138:140-149.
63. Spigoni V, Fantuzzi F, Fontana A, Cito M, Derlindati E, Zavaroni I, Cnop M, Bonadonna RC and Dei Cas A. Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells. *Atherosclerosis* 2017, 265:162-171.
64. Cunha DA, Cito M, Grieco FA, Cosentino C, Danilova T, Ladriere L, Lindahl M, Domanskyi A, Bugliani M, Marchetti P, Eizirik DL and Cnop M. Pancreatic  $\beta$ -cell protection from inflammatory stress by the endoplasmic reticulum proteins thrombospondin 1 and mesencephalic astrocyte-derived neurotrophic factor (MANF). *J Biol Chem* 2017, 292:14977-14988.
65. Patel KA, Kettunen J, Laakso M, Stančáková A, Laver TW, Colclough K, Johnson MB, Abramowicz M, Groop L, Miettinen PJ, Sheppard MH, Flanagan SE, Ellard S, Inagaki N, Hattersley AT, Tuomi T, Cnop M\* and Weedon MN\*. Heterozygous *RFX6* protein truncating variants are associated with Maturity-Onset Diabetes of the Young (MODY) with reduced penetrance. *Nat Commun* 2017, 8:888. \*shared last and corresponding authorship
66. Ciregia F, Bugliani M, Ronci M, Giusti L, Boldrini C, Mazzoni MR, Mossuto S, Grano F, Cnop M, Marselli L, Giannaccini G, Urbani A, Lucacchini A and Marchetti P. Palmitate-induced lipotoxicity alters acetylation of multiple proteins in clonal  $\beta$  cells and human pancreatic islets. *Sci Rep* 2017, 7:13445.
67. Calderari S, Ria M, Gérard C, Nogueira TC, Villate O, Collins SC, Neil H, Gervasi N, Hue C, Suarez-Zamorano N, Prado C, Cnop M, Bihoreau MT, Kaisaki PJ, Cazier JB, Julier C, Lathrop M, Werner M, Eizirik DL and Gauguier D. Molecular genetics of the transcription factor GLIS3 identifies its dual function in beta cells and neurons. *Genomics* 2018, 110:98-111.
68. Paula FMM, Leite NC, Borck PC, Freitas-Dias R, Cnop M, Chacon-Mikahil MPT, Cavaglieri CR, Marchetti P, Boschero AC, Zoppi CC and Eizirik DL. Exercise training protects human and rodent  $\beta$  cells against endoplasmic reticulum stress and apoptosis. *FASEB J* 2018, published online November 13.

69. Cosentino C, Toivonen S, Atta M, Ravanat JL, Demine S, Diaz Villamil E, Pachera N, Balboa D, Otonkoski T, Deglasse JP, Jonas JC, Pearson ER, Eizirik DL, Cnop M\* and Igoillo-Esteve M\*. tRNA hypomethylation: a novel mechanism of pancreatic  $\beta$  cell demise in diabetes. Submitted. \*shared last and corresponding authorship
70. Montagne L, Derhourhi M, Piton A, Toussaint B, Durand E, Vaillant E, Thuillier D, Gaget S, De Graeve F, Rabearivelo I, Desailoud R, Cnop M, Nicolescu R, Cohen L, Zagury JF, Amouyal M, Weill J, Muller J, Sand O, Delobel B, Froguel P, Bonnefond A. Optimized diagnosis of intellectual disability and obesity by an augmented whole-exome sequencing. Submitted.
71. Cito M, Cunha DA, Bugliani M, Dei Cas A, Marchetti P, Bonadonna RC, Eizirik DL and Cnop M. Heme-regulated inhibitor (HRI) mediates pancreatic  $\beta$  cell survival through Akt/BAD and JNK pathways. Manuscript in preparation.
72. Igoillo-Esteve M, Oliveira AF, Abdulkarim B, Rai M, Pandolfo M, Eizirik DL and Cnop M. Impact of metabolic stress and GLP-1 agonist therapy on glucose metabolism in a mouse model of Friedreich ataxia. Manuscript in preparation.
73. Salpea P, Abdulkarim B, Senée V, Philippi A, Singh P, Daures M, Igoillo-Esteve M, Chausseot A, Nicolino M, Eizirik DL, Julier C and Cnop M. Novel loss-of-function mutations in *DNAJC3* as a cause of young-onset diabetes due to oxidative stress and mitochondrial  $\beta$ -cell apoptosis. Manuscript in preparation.
74. Lytrivi M, Lopes M, Ghaddar K, Igoillo-Esteve M, Cunha DA, Marchetti P, Ortsäter H, Eizirik DL and Cnop M. Combined transcriptome and proteome profiling of the pancreatic  $\beta$  cell response to palmitate unveils novel mechanisms of  $\beta$  cell pathophysiology in type 2 diabetes. Manuscript in preparation.

#### Reviews, guidelines and commentaries

75. Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S and Eizirik DL. Mechanisms of  $\beta$  cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* 2005, 54:S97-S107. [IF 8.028; RCR 17.66]
76. Eizirik DL, Cardozo AK and Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. *Endocr Rev* 2008, 29:42-61. [IF 18.562; RCR 19.08]
77. Cnop M. Fatty acids and glucolipototoxicity in the pathogenesis of type 2 diabetes. *Biochem Soc Trans* 2008, 36:348-352. [IF 2.979; RCR 3.36]
78. Cnop M, Igoillo-Esteve M, Cunha DA, Ladrière L and Eizirik DL. An update on lipotoxic endoplasmic reticulum stress in pancreatic  $\beta$  cells. *Biochem Soc Trans* 2008, 36:909-915. [IF 2.979; RCR 1.57]
79. Eizirik DL and Cnop M. ER stress in pancreatic  $\beta$  cells: the thin red line between adaptation and failure. *Sci Signal* 2010, 3:pe7. [IF 6.120; RCR 2.39]
80. Cnop M, Ladrière L, Igoillo-Esteve M, Moura RF and Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic  $\beta$ -cell dysfunction. *Diabetes Obes Metab* 2010, 12 S2:76-82. [IF 3.415; RCR 2.70]
81. Cnop M, Igoillo-Esteve M, Hughes SJ, Walker JN, Cnop I and Clark A. Longevity of human islet  $\alpha$  and  $\beta$  cells. *Diabetes Obes Metab* 2011, 13 S1:39-46. [IF 3.379; RCR 1.05]
82. Cnop M, Foufelle F and Velloso LA. Endoplasmic reticulum stress, obesity and diabetes. *Trends Mol Med* 2012, 18:59-68. [IF 9.571; RCR 11.06]
83. Cnop M. High fat feeding exacerbates endoplasmic reticulum stress and beta cell demise. *Eur J Lipid Sci Technol* 2012, 114:229-232. [IF 2.266]
84. Eizirik DL and Cnop M. Mining genes in type 2 diabetic islets and finding gold. *Cell Metab* 2012, 16:555-557. [IF 14.619; RCR 0.06]
85. Cnop M, Mulder H and Igoillo-Esteve M. Diabetes in Friedreich ataxia. *J Neurochem* 2013, 126 Suppl 1:94-102. [IF 4.244; RCR 1.52]



86. Velloso LA, Eizirik DL and Cnop M. Type 2 diabetes mellitus - an autoimmune disease? *Nat Rev Endocrinol* 2013, 9:750-755. [IF 12.958; RCR 2.06]
87. Gotthardt M, Eizirik DL, Cnop M and Brom M. Beta cell imaging - a key tool in optimized diabetes prevention and treatment. *Trends Endocrinol Metab* 2014, 25:375-377. [IF 9.392; RCR 1.20]
88. Cnop M. Women in metabolism - Miss  $\beta$  cell. *Cell Metab* 2015, 22:952. [IF 17.303]
89. Klionsky DJ et al (2000 co-authors). Guidelines for the use and interpretation of assays for monitoring autophagy (3<sup>rd</sup> edition). *Autophagy* 2016, 12:1-222. [IF 8.593]
90. Cnop M, Toivonen S, Igoillo-Esteve M and Salpea P. Endoplasmic reticulum stress and eIF2 $\alpha$  phosphorylation: the Achilles heel of pancreatic  $\beta$  cells. *Mol Metab* 2017, 6:1024-1039.
91. Cnop M, Klupa T, Tentolouris N, Novials A, Burcelin R and Van Eimeren M. Europe has to step up its efforts to produce innovative and safe diabetes technology. *Diabetologia* 2017, 60:2532-2533.
92. Chase JG, Desai T, Bohe J, Cnop M, De Block C, Gunst J, Hovorka R, Kalfon P, Krinsley J, Renard E and Preiser JC. Improving glycemic control in the critically ill: personalized care to mimic the endocrine pancreas. Manuscript in preparation.
93. Lytrivi M and Cnop M. Protecting islet  $\beta$  cells from inflammatory stress: implications for therapies for type 2 diabetes. Invited review for *Curr Opin Pharmacol*, in preparation.

#### Abstracts

1. 32<sup>nd</sup> EASD Annual Meeting, Vienna, Austria, 1996. Cnop M, Gruppig A and Pipeleers D. LDL-toxicity in rat  $\beta$  cells. *Diabetologia* 39, A130, 1996.
2. 32<sup>nd</sup> EASD Annual Meeting, Vienna, Austria, 1996. Gruppig A, Cnop M, Van Schravendijk C, Van Berkel T and Pipeleers D. LDL-binding and uptake by islet  $\beta$  cells. *Diabetologia* 39, A130, 1996.
3. 24<sup>th</sup> International Congress of Internal Medicine, Lima, Peru, 1998. Cnop M, Decochez K, Op de Beeck B, Keuppens F and Keymeulen B. Treatment of retroperitoneal fibrosis with tamoxifen.
4. Annual meeting of the EASD Islet Study Group, Durbuy, Belgium, 1999. Cnop M, Gruppig A, Hoorens A, Bouwens L, Marichal M and Pipeleers D. Endocytosis of (very) low density lipoprotein by human pancreatic  $\beta$  cells and uptake in lipid-storing vesicles which increase with age. *Diabetes and Metabolism* 25, VII, 1999.
5. 36<sup>th</sup> EASD Annual Meeting, Jerusalem, Israel, 2000. Cnop M, Hannaert JC, Hoorens A, Eizirik DL and Pipeleers D. Inverse relationship between cytotoxicity of free fatty acids for pancreatic islet cells and cellular triglyceride accumulation. *Diabetologia* 43, A64, 2000.
6. 36<sup>th</sup> Meeting of the Scandinavian Society for the Study of Diabetes, Uppsala, Sweden, 2001. Cnop M, Havel PJ, Vidal J, Hull RL, Wang F, Carr DR, Retzlaff BM, Knopp RH and Kahn SE. Distribution of abdominal fat differentially affects plasma leptin levels and insulin sensitivity in nonobese subjects. *Uppsala Journal of Medical of Sciences* 106 S2, 17, 2001.
7. 61<sup>st</sup> Scientific Sessions of the American Diabetes Association, Philadelphia, USA, 2001. Cnop M, Havel PJ, Vidal J, Hull RL, Wang F, Carr DR, Retzlaff BM, Knopp RH and Kahn SE. Distribution of abdominal fat differentially affects plasma leptin levels and insulin sensitivity in nonobese subjects. *Diabetes* 50 S2, A371, 2001.
8. 61<sup>st</sup> Scientific Sessions of the American Diabetes Association, Philadelphia, USA, 2001. Vidal J, Cnop M, Wang F, Hull RL, Carr DR, Retzlaff BM, Knopp RH and Kahn SE. Intra-abdominal fat is associated with insulin resistance and impaired  $\beta$ -cell compensation for that insulin resistance. *Diabetes* 50 S2, A319, 2001.
9. 61<sup>st</sup> Scientific Sessions of the American Diabetes Association, Philadelphia, USA, 2001. Wang F, Vidal J, Hull RL, Cnop M and Kahn SE. Islet amyloid deposition is associated with reduced  $\beta$ -cell mass in a mouse model of islet amyloid. *Diabetes* 50 S2, A32, 2001.

10. 61<sup>st</sup> Scientific Sessions of the American Diabetes Association, Philadelphia, USA, 2001. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M and Kahn SE. Increased dietary fat promotes islet amyloid formation and  $\beta$ -cell secretory dysfunction in a mouse model of islet amyloid. *Diabetes* 50 S2, A313, 2001.
11. 61<sup>st</sup> Scientific Sessions of the American Diabetes Association, Philadelphia, USA, 2001. Hull RL, Vidal J, Wang F, Cnop M, Carr DR and Kahn SE. Proislet amyloid polypeptide is a normal circulating peptide in healthy human subjects and is released via the constitutive secretory pathway. *Diabetes* 50 S2, A313, 2001.
12. Workshop on the Endocrine Pancreas, Brussels, Belgium, 2001. Cnop M, Havel PJ, Vidal J, Hull RL, Wang F, Carr DR, Retzlaff BM, Knopp RH and Kahn SE. The concurrent deposition of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations in nonobese subjects. *Diabetes and Metabolism* 28, 3S102, 2002.
13. 62<sup>nd</sup> Scientific Sessions of the American Diabetes Association, San Francisco, USA, 2002. Cnop M, Havel PJ, Utzschneider KM, Carr DR, Retzlaff BM, Knopp RH and Kahn SE. Gender-based differences in adiponectin and leptin levels are related to differences in body fat distribution. *Diabetes* 51 S2, A404, 2002.
14. 62<sup>nd</sup> Scientific Sessions of the American Diabetes Association, San Francisco, USA, 2002. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID Study Group.  $\beta$  cell function is a major contributor to oral glucose tolerance in first-degree relatives of four ethnic groups in the United States. *Diabetes* 51 S2, A230, 2002.
15. Eric K. Fernström Foundation Symposium, Diabetes – a focus on the  $\beta$  cell, Ystads Saltsjöbad, Sweden, 2002. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Boyko EJ, Knopp RH and Kahn SE. Distinct relationships of adiponectin and leptin to body fat distribution and insulin sensitivity.
16. Congress of the Belgian Society of Internal Medicine, Ghent, Belgium, 2002. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Gingerich RL, Boyko EJ, Knopp RH and Kahn SE. Increased intra-abdominal fat is associated with decreased adiponectin secretion, leading to insulin resistance and dyslipidemia.
17. American Society of Hypertension 18<sup>th</sup> Annual Scientific Meeting, New York, USA, 2003. Ciarka A, Velez-Roa S, Cnop M, Najem B, Naeije R, Degaute JP, Fery F and van de Borne P. Insulin and chemoreceptors sensitivity. *Am J Hypertens* 17 S1, S210, 2004.
18. Annual meeting of the EASD Islet Study Group, Brussels, Belgium, 2003. Cnop M, Fujimoto WY and Kahn SE. A progressive decline in  $\beta$  cell function is the main determinant of decreasing glucose tolerance in subjects at high risk of developing type 2 diabetes. *Diabetes and Metabolism*.
19. Annual Scientific Sessions of the American College of Cardiology, New Orleans, USA, 2004. Ciarka A, Velez-Roa S, Bareels V, Cnop M, Fery F, Naeije R, Degaute JP, Somers V and van de Borne P. Acute hyperinsulinemia does not increase chemoreflex sensitivity.
20. 20<sup>th</sup> Scientific Meeting of the International Society of Hypertension, Sao Paulo, Brazil, 2004. Ciarka A, Velez-Roa S, Bareels V, Cnop M, Fery F, Naeije R, Degaute JP and van de Borne P. Effects of insulin on chemoreflex sensitivity. *J Hypertens* 22 S1, S23, 2004.
21. 23<sup>rd</sup> Annual Scientific Meeting of the Belgian Society of Cardiology, Brussels, Belgium, 2004. Ciarka A, Velez-Roa S, Bareels V, Cnop M, Fery F, Naeije R, Degaute JP, Somers V and van de Borne P. Chemoreflex sensitivity during high dose insulin infusion.
22. 39<sup>th</sup> Meeting of the Scandinavian Society for the Study of Diabetes, Trondheim, Norway, 2004. Cnop M, Fujimoto WY and Kahn SE. A progressive decline in  $\beta$  cell function is the main determinant of decreasing glucose tolerance in subjects at high risk of developing type 2 diabetes. *Upsala Journal of Medical of Sciences*, 2004.
23. 64<sup>th</sup> Scientific Sessions of the American Diabetes Association, Orlando, USA, 2004. Cnop M, Fujimoto WY and Kahn SE. A progressive decline in  $\beta$  cell function is the main determinant of decreasing glucose tolerance in first-degree relatives of type 2 diabetic subjects. *Diabetes* 53 S2, A356, 2004.

24. 40<sup>th</sup> EASD Annual Meeting, Munich, Germany, 2004. Kharroubi I, Ladriere L, Cardozo AK, Cnop M and Eizirik DL. Free fatty acids and cytokines induce pancreatic  $\beta$  cell apoptosis by distinctly different mechanisms: role of NF- $\kappa$ B and endoplasmic reticulum stress. *Diabetologia* 47 S1, A176, 2004.
25. 65<sup>th</sup> Scientific Sessions of the American Diabetes Association, San Diego, USA, 2005. Kharroubi I, Lee C-H, Darville M, Evans R, Eizirik DL and Cnop M. The PPAR- $\delta$  gene network is expressed and regulated by cytokines in pancreatic  $\beta$  cells. *Diabetes* 54 S1, A400, 2005.
26. 41<sup>st</sup> EASD Annual Meeting, Athens, Greece, 2005. Cnop M, Kharroubi I, Welsh N and Eizirik DL. Is there a role for locally produced inflammatory mediators in glucotoxicity to human pancreatic islets? *Diabetologia* 48 S1, A51, 2005.
27. 41<sup>st</sup> EASD Annual Meeting, Athens, Greece, 2005. Kharroubi I, Lee C-H, Darville M, Evans R, Eizirik DL and Cnop M. PPAR- $\delta$  is expressed and regulated by cytokines in pancreatic  $\beta$  cells. *Diabetologia* 48 S1, A158, 2005.
28. International Group on Insulin Secretion Symposium VI, Cap Ferrat, France, 2005. Cnop M, Kharroubi I, Cardozo AK and Eizirik DL. The endoplasmic reticulum stress response in  $\beta$  cells: differential effects of free fatty acids, glucose and cytokines. *Diabetes* 54 S2, S163, 2005.
29. 41<sup>st</sup> EASD Annual Meeting, Athens, Greece, 2005. Cnop M. From bedside to bench: the role of fat in  $\beta$ -cell loss in type 2 diabetes. *Diabetologia* 48, R105-R106, 2005.
30. Integrated European Union Workshop on  $\beta$  cell destruction in type 1 diabetes, Leiden, the Netherlands, 2006. Cardozo AK, Pirot P, Ortis F, Cnop M, Ma Y, Hendershot L and Eizirik DL. Role of C/EBP/ATF and AP-1 sites on the transcriptional regulation of the endoplasmic reticulum stress-induced gene CHOP in insulin-producing cells.
31. Integrated European Union Workshop on  $\beta$  cell destruction in type 1 diabetes, Leiden, the Netherlands, 2006. Cnop M, Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM and Eizirik DL. BCL-6 - the missing link for anti-inflammatory PPAR- $\delta$  signaling in pancreatic  $\beta$ -cells?
32. Annual meeting of the EASD Islet Study Group, Helsingor, Denmark, 2006. Cnop M, Ladriere L, Hekerman P, Ortis F, Cardozo AK, Boyce M, Yuan J and Eizirik DL. Selective inhibition of eIF2 $\alpha$  dephosphorylation potentiates fatty acid-induced ER stress and causes pancreatic  $\beta$ -cell apoptosis.
33. SFE-Alfediam Meeting, Marseille, France, 2007. Begu A, Depondt C, Pandolfo M, Fery F and Cnop M. Relative contribution of impaired insulin secretion and insulin action in the pathogenesis of impaired glucose tolerance in Friedreich's ataxia. *Diabetes and Metabolism* 33, S28, 2007.
34. 67<sup>th</sup> Scientific Sessions of the American Diabetes Association, Chicago, USA, 2007. Cnop M, Begu A, Depondt C, Pandolfo M and Fery F. Beta-cell dysfunction causes impaired glucose tolerance in Friedreich ataxia. *Diabetes* 56 S1, Late Breaking Abstract 035, 2007.
35. 43<sup>rd</sup> EASD Annual Meeting, Amsterdam, The Netherlands, 2007. Ladriere L, Hekerman P, Cunha DA, Bazarra-Castro A, Ortis F, Eizirik DL and Cnop M. Molecular mechanisms implicated in free fatty acid-induced ER stress and pancreatic beta cell apoptosis. *Diabetologia* 50 S1, S44, 2007.
36. 43<sup>rd</sup> EASD Annual Meeting, Amsterdam, The Netherlands, 2007. Marchetti P, Masini M, Bugliani M, Lupi R, Marselli L, Del Prato S, Weir G, Eizirik DL and Cnop M. Endoplasmic reticulum stress markers in pancreatic beta cells from type 2 diabetic subjects. *Diabetologia* 50 S1, S44, 2007.
37. 43<sup>rd</sup> EASD Annual Meeting, Amsterdam, The Netherlands, 2007. Cnop M, Begu A, Depondt C, Pandolfo M and Fery F. Relative contribution of insulin resistance and pancreatic beta cell dysfunction in the pathogenesis of impaired glucose tolerance in Friedreich ataxia. *Diabetologia* 50 S1, S27, 2007.

38. Annual meeting of the EASD Islet Study Group, Brussels, Belgium, 2007. Cunha DA, Eizirik DL and Cnop M. Effects of exendin-4 on free fatty acid-induced endoplasmic reticulum stress and apoptosis in pancreatic beta cells.
39. Artificial Insulin Delivery and Pancreas and Islet Transplantation workshop, Igls-Innsbruck, Austria, 2008. Hughes SJ, Cnop M, F. Sayeed F, van de Laar L, Moffitt JH, Gray DWG, Johnson PRV, Hansen BC, Morris JF, Pipeleers-Marichal M and Clark A. Longevity of islet beta cells estimated by lipofuscin accumulation indicates low cellular turnover in man and monkeys.
40. 68<sup>th</sup> Scientific Sessions of the American Diabetes Association, San Francisco, USA, 2008. Clark A, Hughes SJ, Sayeed F, van de Laar L, Moffitt JH, Gray DWG, Johnson PRV, Morris JF, Pipeleers-Marichal M, Cnop M and Hansen BC. Longevity of islet beta cells estimated by lipofuscin accumulation indicates low cellular turnover in man and monkeys. *Diabetes* 57 S1, A448, 2008.
41. 44<sup>th</sup> EASD Annual Meeting, Rome, Italy, 2008. Ladrière L, Igoillo-Esteve M, Cunha DA, Brion JP, Lupi R, Marchetti P, Eizirik DL and Cnop M. Free fatty acid-induced endoplasmic reticulum stress signaling and apoptosis in human pancreatic islets. *Diabetologia* 51 S1, S61, 2008.
42. 44<sup>th</sup> EASD Annual Meeting, Rome, Italy, 2008. Cnop M, Hughes SJ, Sayeed F, van de Laar L, Gunter JH, Gray DWG, Johnson PRV, Hansen BC, Morris JF, Pipeleers-Marichal M, Cnop I and Clark A. Long life span and very low neogenesis and proliferation of human islet  $\beta$ -cells estimated by mathematical modelling of  $\beta$ -cell lipofuscin accumulation. *Diabetologia* 51 S1, S185, 2008.
43. 44<sup>th</sup> EASD Annual Meeting, Rome, Italy, 2008. Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Eizirik DL and Cnop M. Effects of exendin-4 on free fatty acid-induced endoplasmic reticulum stress and apoptosis in pancreatic beta cells. *Diabetologia* 51 S1, S209, 2008.
44. International Congress of Endocrinology, Rio de Janeiro, Brazil, 2008. Cnop M, Hughes SJ, Sayeed F, van de Laar L, Gunter JH, Gray DWG, Johnson PRV, Hansen BC, Morris JF, Pipeleers-Marichal M, Cnop I and Clark A. Long life span of human pancreatic  $\beta$ -cells estimated by mathematical modeling of  $\beta$ -cell lipofuscin accumulation.
45. Annual meeting of the EASD Islet Study Group, Rome, Italy, 2008. Igoillo-Esteve M, Marselli L, Lupi R, Cunha DA, Ladrière L, Ortis F, Weir G, Marchetti P, Eizirik DL and Cnop M. The increased chemokine and cytokine expression by human islets in type 2 diabetes is mimicked by in vitro human islet exposure to palmitate.
46. 69<sup>th</sup> Scientific Sessions of the American Diabetes Association, New Orleans, USA, 2009. Casteels K, Cnop M and Mathieu C. Sex difference in metabolic abnormalities in offspring born to diabetic mothers and fathers. *Diabetes* 58 S1, A469, 2009.
47. 10<sup>th</sup> Immunology of Diabetes Society congress, Malmö, Sweden, 2009. Moore F, Colli ML, Cnop M, Igoillo Esteve M, Cardozo AK, Cunha DA, Bugliani M, Marchetti P and Eizirik DL. PTPN2, a candidate gene for type 1 diabetes, modulates interferon- $\gamma$ -induced pancreatic  $\beta$ -cell apoptosis.
48. 44<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, 2009. Vos B, Moreno C, Nagy N, Fery F, Cnop M, Deviere J and Adler M. Non obese, non diabetic patients presenting with non alcoholic fatty liver disease: an expandable clinico-pathological entity. *J Hepatol* 50 S1, S373, 2009.
49. 45<sup>th</sup> EASD Annual Meeting, Vienna, Austria, 2009. Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Gurzov EN, Eizirik DL and Cnop M. Exendin-4 and cAMP protect pancreatic beta cells from lipotoxic ER stress via induction of antiapoptotic defense mechanisms. *Diabetologia* 52 S1, S149, 2009.
50. 45<sup>th</sup> EASD Annual Meeting, Vienna, Austria, 2009. Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Weir G, Marchetti P, Eizirik DL and Cnop M. Exposure of human islets to palmitate mimics the mild inflammatory response observed in islets from type 2 diabetic individuals. *Diabetologia* 52 S1, S164, 2009.

51. 46<sup>th</sup> EASD Annual Meeting, Stockholm, Sweden, 2010. Lemaire K, Moura RF, Granvik M, Hohmeier HE, Hendrickx N, Waelkens E, Newgard CB, Cnop M and Schuit F. New players in the beta cell ER stress response: UFM1 and UFBP1. *Diabetologia* 53 S1, S211, 2010.
52. Annual meeting of the EASD Islet Study Group, Tällberg, Sweden, 2010. Igoillo-Esteve M, Gurzov EN, Eizirik DL and Cnop M. The transcription factor B-Cell Lymphoma (BCL)-6 modulates pancreatic  $\beta$ -cell inflammatory responses.
53. Annual meeting of the EASD Islet Study Group, Tällberg, Sweden, 2010. Serroukh Y, Igoillo-Esteve M, Rai M, Depondt C, Begu A, Musuaya AE, Neef MA, Pandolfo M, Eizirik DL, Féry F and Cnop M. Pancreatic  $\beta$ -cell dysfunction contributes to impaired glucose tolerance in Friedreich's ataxia.
54. Annual meeting of the EASD Islet Study Group, Natal, Brazil, 2011. Cunha DA, Gurzov EN, Germano CM, Naamane N, Eizirik DL and Cnop M. Lipotoxic ER stress-induced DP5 and PUMA contribute to mitochondrial  $\beta$ -cell apoptosis.
55. 4<sup>th</sup> International Friedreich's Ataxia Scientific Conference, Strasbourg, France, 2011. Igoillo-Esteve M, Serroukh Y, Rai M, Depondt C, Begu A, Musuaya AE, Ladriere L, Moore F, Marchetti P, Pandolfo M, Eizirik DL, Féry F and Cnop M. Role and mechanisms of pancreatic  $\beta$ -cell failure in diabetes in Friedreich's ataxia.
56. 47<sup>th</sup> EASD Annual Meeting, Lisbon, Portugal, 2011. Igoillo-Esteve M, Serroukh Y, Rai M, Depondt C, Begu A, Musuaya AE, Ladriere L, Moore F, Marchetti P, Pandolfo M, Eizirik DL, Féry F and Cnop M. Metabolic stress-induced  $\beta$ -cell failure contributes to diabetes in Friedreich's ataxia. *Diabetologia* 54 S1, 2011.
57. 19<sup>th</sup> European Cell Death Organization Conference on Apoptosis - Metabolism, Epigenetics and Death, Stockholm, Sweden, 2011. Ladrière L, Igoillo-Esteve M, Serroukh Y, Marchetti P, Pandolfo M, Féry F, Eizirik DL and Cnop M. Role for endoplasmic reticulum stress in pancreatic  $\beta$ -cell apoptosis in mitochondrial diabetes of Friedreich's ataxia.
58. 3<sup>rd</sup> Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD), Smolenice, Slovakia, 2011. Igoillo-Esteve M, Serroukh Y, Rai M, Depondt C, Begu A, Musuaya AE, Ladrière L, Moore F, Marfour I, Marchetti P, Koeppen AH, Pandolfo M, Eizirik DL, Féry F and Cnop M. Mitochondrial dysfunction and endoplasmic reticulum stress cause  $\beta$ -cell failure in diabetes in Friedreich's ataxia.
59. 8<sup>th</sup> World Meeting on Pharmaceuticals, Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey, 2012. Depreter F, Burniat A, Blocklet D, Lacroix S, Cnop M, Féry F, Van Aelst N, Pilcer G, Deleers M, Goldman S and Amighi K. Clinical evaluation of two new formulations of inhaled insulin in type 1 diabetic patients.
60. 48<sup>th</sup> EASD Annual Meeting, Berlin, Germany, 2012. Cnop M, Bottu G, Griebel T, Abdulkarim B, Marselli L, Marchetti P, McCarthy MI, Sammeth M and Eizirik DL. RNA-sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. *Diabetologia* 55 S1, S214, 2012.
61. Annual meeting of the EASD Islet Study Group, Rostock, Germany, 2012. Igoillo-Esteve M, Abdulkarim B, Eizirik DL and Cnop M. The intrinsic pathway of apoptosis is triggered in frataxin-deficient  $\beta$ -cells via activation of the Bcl-2 proteins Bad, DP5 and Bim.
62. Annual meeting of the EASD Islet Study Group, Rostock, Germany, 2012. Cunha DA, Gurzov EN, Ortis F, Naamane N, Bugliani M, Marchetti P, Eizirik DL and Cnop M. JunB prevents lipotoxic  $\beta$ -cell death via modulation of AKT and the ER stress response.
63. Beta Cell Workshop 2013, Kyoto, Japan, 2013. Cnop M, Bottu G, Griebel T, Abdulkarim B, Marselli L, Marchetti P, McCarthy MI, Sammeth M and Eizirik DL. The transcriptome of metabolically stressed human islets.
64. 4<sup>th</sup> Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD), Malmo, Sweden, 2013. Abdulkarim B, Bottu G, Griebel T, Marselli L, Marchetti P, McCarthy MI, Sammeth M, Eizirik DL and Cnop M. RNA-sequencing of palmitate-treated human islets identifies GATA6 inhibition as a potential mediator of lipotoxicity.

65. 73<sup>rd</sup> Scientific Sessions of the American Diabetes Association, Chicago, USA, 2013. Cnop M, Bottu G, Griebel T, Abdulkarim B, Marselli L, Marchetti P, McCarthy MI, Sammeth M and Eizirik DL. The transcriptome of metabolically stressed human islets. *Diabetes* 62 S1, LB51, 2013.
66. 73<sup>rd</sup> Scientific Sessions of the American Diabetes Association, Chicago, USA, 2013. Suleiman M, Bugliani M, Syed F, Olimpico F, Mariotti L, Fornaciari S, Focosi D, Scatena F, Boggi U, Filipponi F, Marchetti P, Eizirik DL, Cnop M and Marselli L. Dissecting the factors affecting the functional properties of isolated human islets. *Diabetes* 62 S1, A577, 2013.
67. Kickoff meeting of the Belgian Medical Genomics Initiative, Leuven, Belgium, 2013. Igoillo-Esteve M, Genin A, Lambert N, Pirson I, Abdulkarim B, Lambert N, Simonis N, Drielsma A, Marselli L, Marchetti P, Eizirik DL, Wuyts W, Julier C, Chakera AJ, Ellard S, Hattersley A, Vanderhaeghen P, Abramowicz M and Cnop M. tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans.
68. 49<sup>th</sup> EASD Annual Meeting, Barcelona, Spain, 2013. Igoillo-Esteve M, Gurgul-Convey E, Lenzen S, Eizirik DL and Cnop M. Oxidative stress and activation of the intrinsic pathway of apoptosis cause  $\beta$ -cell loss in Friedreich's ataxia. *Diabetologia* 56 S1, S202, 2013.
69. 49<sup>th</sup> EASD Annual Meeting, Barcelona, Spain, 2013. Cunha DA, Gurzov EN, Ortis F, Naamane N, Bugliani M, Marchetti P, Eizirik DL and Cnop M. The transcription factor JunB protects  $\beta$ -cells from lipotoxicity by induction of the ER stress response gene XBP1 and AKT signaling. *Diabetologia* 56 S1, S112, 2013.
70. Annual meeting of the EASD Islet Study Group, Sitges, Spain, 2013. Igoillo-Esteve M, Genin A, Pirson I, Abdulkarim B, Simonis N, Drielsma A, Marselli L, Marchetti P, Eizirik DL, Wuyts W, Julier C, Chakera AJ, Ellard S, Hattersley AT, Abramowicz M and Cnop M. Loss-of-function of the tRNA methyltransferase homolog gene TRMT10A causes young onset diabetes and primary microcephaly in humans.
71. Annual meeting of the EASD Islet Study Group, Sitges, Spain, 2013. Abdulkarim B, Bottu G, Griebel T, Marselli L, Cunha DA, Marchetti P, McCarthy MI, Sammeth M, Eizirik DL and Cnop M. Functional genomic analysis of human islets exposed to palmitate identifies GATA6 inhibition as a potential mediator of lipotoxicity.
72. Fourth Belgian Nutrition Society Symposium 2014: Genes and nutrition, is personalised nutrition the next realistic step? Brussels, Belgium, 2014. Cnop M. Epigenetic aspects of pancreatic  $\beta$  cell function in type 2 diabetes. *Archives of Public Health* 72 Suppl 1, K1, 2014.
73. 24<sup>th</sup> European Congress of Perinatal Medicine, Firenze, Italy, 2014. Gironi P, Gerday C, Kirkpatrick C and Cnop M. Incidence of gestational diabetes mellitus and perinatal outcomes using the IADPSG guidelines.
74. French Nutrition Days, Brussels, Belgium, 2014. Pachikian BD, Baret P, Bindelle J, Cleeremans A, Cnop M, Luminet O, Moser M, Paquot N, Stassart PM, Thissen JP and Delzenne NM. The FOOD4GUT project: innovative nutritional approach to obesity using prebiotics.
75. International Ataxia Research Conference 2015, Windsor, UK, 2015. Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, Jonas JC, Pandolfo M, Eizirik DL and Cnop M. Incretin analogs as new therapeutic agents for Friedreich's ataxia.
76. International Ataxia Research Conference 2015, Windsor, UK, 2015. Oliveira A, Rai M, Pachera N, Abdulkarim B, Pandolfo M, Eizirik DL, Cnop M and Igoillo-Esteve M. Exendin-4 improves  $\beta$ -cell function and glucose tolerance in KIKO mice.
77. International Ataxia Research Conference 2015, Windsor, UK, 2015. Hu A, Mangiameli E, Pelizzoni I, Oliveira A, Rai M, Eizirik DL, Cnop M, Igoillo-Esteve M, Grohovaz F, Codazzi F and Pandolfo M. Induced pluripotent stem cell-derived neurons from Friedreich's ataxia patients have a cellular phenotype that can be reversed by frataxin inducers.
78. American Academy of Neurology 67<sup>th</sup> Annual Meeting, Washington, DC, 2015. Pandolfo M, Igoillo-Esteve M, Hu A, Gurgul-Convey E, Romagueira Bichara Dos Santos L, Jonas

- JC, Eizirik DL and Cnop M. Study of  $\beta$  cells and neurons indicate incretin analogs as potential therapeutics for Friedreich's ataxia.
79. Annual meeting of the EASD Islet Study Group, Jerusalem, Israel, 2015. Abdulkarim B, Hernangómez M, Ladrière L, Marchetti P, Eizirik DL and Cnop M. Guanabenz sensitizes  $\beta$  cells to endoplasmic reticulum stress-induced apoptosis.
  80. Annual meeting of the EASD Islet Study Group, Jerusalem, Israel, 2015. Igoillo-Esteve M, Oliveira A, Rai M, Pachera N, Abdulkarim B, Pandolfo M, Eizirik DL and Cnop M. Exendin-4 improves  $\beta$  cell function and glucose tolerance in KIKO mice.
  81. 75<sup>th</sup> Scientific Sessions of the American Diabetes Association, Boston, USA, 2015. Bugliani M, Masini M, Syed F, Mossuto S, Suleiman M, Marselli L, Boggi U, Filipponi F, Eizirik DL, Cnop M, Masiello P and Marchetti P. Autophagy induction improves function and survival of human type 2 diabetic  $\beta$ -cells. *Diabetes* 64 S1, A574, 2015.
  82. 51<sup>st</sup> EASD Annual Meeting, Stockholm, Sweden, 2015. Cunha DA, Carlsson P, Molkenin JD, Bugliani M, Marchetti P, Eizirik DL and Cnop M. Thrombospondin 1 induces an anti-oxidant response via the PERK-NRF2 pathway and protects  $\beta$  cells from lipotoxicity. *Diabetologia* 58 S1, S46, 2015.
  83. 51<sup>st</sup> EASD Annual Meeting, Stockholm, Sweden, 2015. Abdulkarim B, Nicolino M, Igoillo-Esteve M, Daures M, Romero S, Philippi A, Senée V, Lopes M, Cunha DA, Harding HP, Bendelac N, Hattersley AT, Eizirik DL, Ron D, Cnop M and Julier C. CReP loss-of-function causes  $\beta$  cell failure and diabetes. *Diabetologia* 58 S1, S132, 2015.
  84. 12<sup>th</sup> European Nutrition Conference FENS, Berlin, Germany, 2015. Neyrinck A, Pachikian B, Kambashi B, Bindelle J, Cleeremans A, Luminet O, Paquot N, Cnop M, Thissen JP and Delzenne N. Clinical trial: To test for prebiotics on metabolic, inflammatory and behavioral disorders in obese population.
  85. French Diabetes Society (Société Francophone du Diabète), Lyon, France, 2016. Igoillo-Esteve M, Cosentino C, Oltean T, Atta M, Ravanat JL, Eizirik DL and Cnop M. Deficiency in the tRNA methyltransferase TRMT10A activates the intrinsic pathway of apoptosis in pancreatic  $\beta$ -cells.
  86. French Diabetes Society (Société Francophone du Diabète), Lyon, France, 2016. Ghaddar K, Lytrivi M, Lopes M, Igoillo-Esteve M, Cunha DA, Marchetti P, Orsäter H, Eizirik DL and Cnop M. Transcriptome meets proteome: insight into the lipotoxic effect of palmitate in  $\beta$ -cells.
  87. 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, 2016. Cosentino C, Oltean T, Atta M, Ravanat JL, Eizirik DL, Cnop M and Igoillo-Esteve M. Deficiency in the tRNA methyltransferase TRMT10A activates the intrinsic pathway of apoptosis in pancreatic  $\beta$ -cells. Deficiency in the tRNA methyltransferase TRMT10A activates the intrinsic pathway of apoptosis in pancreatic  $\beta$ -cells. *Diabetologia* 59 S1, S167, 2016.
  88. 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, 2016. Cito M, Cunha DA, Bonadonna RC, Eizirik DL and Cnop M. The heme-regulated eIF2 $\alpha$  kinase HRI promotes pancreatic  $\beta$  cell survival through modulation of the Akt/BAD and JNK pathways. *Diabetologia* 59 S1, S208, 2016.
  89. 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, 2016. Cunha DA, Bugliani M, Marchetti P, Eizirik DL and Cnop M. Thrombospondin 1 protects  $\beta$ -cells from proinflammatory cytokines through MANF induction. *Diabetologia* 59 S1, S204, 2016.
  90. 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, 2016. Lytrivi M, Ghaddar K, Lopes M, Igoillo-Esteve M, Cunha DA, Marchetti P, Orsäter H, Eizirik DL and Cnop M. Combined transcriptome and proteome profiling of the  $\beta$ -cell response to palmitate to unveil novel mediators of lipotoxicity. *Diabetologia* 59 S1, S211, 2016.
  91. 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, 2016. Abdulkarim B, Senée V, Philippi A, Singh P, Daures M, Igoillo-Esteve M, Chaussenot A, Nicolino M, Eizirik DL, Julier C and Cnop M. Loss-of-function mutations in *DNAJC3* cause young-onset diabetes due to oxidative stress and mitochondrial  $\beta$ -cell apoptosis. *Diabetologia* 59 S1, S105, 2016.

92. Annual meeting of the Belgian Endocrine Society, La Hulpe, Belgium, 2016. Cosentino C, Atta M, Ravanat JL, Eizirik DL, Cnop M and Igoillo-Esteve M. Unveiling mechanisms of pancreatic  $\beta$ -cell demise in TRMT10A diabetes and identification of  $\beta$ -cell protective approaches.
93. Annual meeting of the Belgian Endocrine Society, La Hulpe, Belgium, 2016. Abdulkarim B, Senée V, Philippi A, Singh P, Daures M, Igoillo-Esteve M, Chausseot A, Nicolino M, Eizirik DL, Julier C and Cnop M. Loss-of-function mutations in DNAJC3 cause young-onset diabetes due to oxidative stress and mitochondrial  $\beta$ -cell apoptosis.
94. French Diabetes Society (Société Francophone du Diabète), Lille, France, 2017. Igoillo-Esteve M, Cosentino C, Atta M, Ravanat JL, Eizirik DL and Cnop M. Elucidation of pathogenic mechanisms of diabetes due to TRMT10A deficiency and identification of novel therapeutic approaches.
95. 77<sup>th</sup> Scientific Sessions of the American Diabetes Association, San Diego, USA, 2017. Patel KA, Laakso M, Stančáková A, Laver T, Colclough K, Johnson M, Kettunen J, Tuomi T, Cnop M, Shepherd MH, Flanagan SE, Ellard S, Hattersley AT and Weedon MN. Heterozygous protein-truncating *RFX6* variants cause MODY with reduced penetrance. Diabetes 66 S1, A6, 2017.
96. Annual meeting of the EASD Islet Study Group, Dresden, Germany, 2017. Cosentino C, Atta M, Ravanat JL, Diaz Villamil E, Toivonen S, Pachera N, Eizirik DL, Cnop M and Igoillo-Esteve M. TRMT10A deficiency causes tRNA hypomethylation and tRNA fragmentation – a novel mechanism for human and rodent  $\beta$  cell demise.
97. 6<sup>th</sup> EASD Study Group on Genetics of Diabetes meeting, Leiden, the Netherlands, 2017. Patel KA, Laakso M, Stančáková A, Laver TW, Colclough K, Johnson MB, Kettunen J, Tuomi T, Cnop M, Shepherd MH, Flanagan SE, Ellard S, Hattersley AT and Weedon MN. Heterozygous *RFX6* protein truncating variants cause Maturity-Onset Diabetes of the Young (MODY) with reduced penetrance.
98. 39<sup>th</sup> ESPEN Congress, The Hague, Netherlands 2017. Hiel S, Rodriguez J, Gianfrancesco M, Portheault D, Kalala G, Neyrinck A, Pachikian BD, Potgens S, Bindels L, Bindelle J, Paquot N, Cnop M, Thissen JP and Delzenne N. Interest of profiling the gut microbiota to evaluate the effect of dietary inulin on obesity-related metabolic disorders in humans: the FOOD4GUT intervention study.
99. ENDO 2018, Chicago, USA, 2018. Syed F, Turatsinze JV, Fuks F, Cnop M, Marchetti P, Ziegler AG, Bonifacio E, Tersey S, Evans-Molina C, Eizirik DL and Mirmira RG. Circulating unmethylated *Cttop* gene as a potential biomarker of islet beta cell death in type 1 diabetes. Endocr Rev in press.
100. European Congress on Obesity, Vienna, Austria, 2018. Hiel S, Rodriguez J, Gianfrancesco M, Portheault D, Kalala G, Mulders K, Chang B, Zamariola G, Neyrinck A, Pachikian B, Potgens S, Frenay C, Bindels L, Cani P, Lanthier N, Trefois P, Klein O, Luminet O, Bindelle J, Paquot N, Cnop M, Thissen JP and Delzenne N. Dietary inulin supplementation promotes weight loss and decreases liver elasticity in obese individuals.
101. Annual Meeting of the International Society for Stem Cell Research, Melbourne, Australia, 2018. Toivonen S, Cosentino C, Pachera N, Balboa D, Otonkoski T, Eizirik DL, Cnop M, Igoillo-Esteve M. Insight into pathogenic mechanisms of TRMT10A deficiency using patient iPSC-derived  $\beta$ -cells: tRNA hypomethylation and fragmentation mediate human  $\beta$ -cell demise. Submitted.